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Abstract
Recent advances in sequencing technology have made it feasible to use next-
generation sequencing (NGS) to characterize the genomic landscape of an indi-
vidual. Unlike microarrays, which are usually only capable of detecting variants
that have been previously discovered in a population, NGS is capable of discern-
ing both common and rare de novo variants.
Sequencing studies that involve the analysis of rare variants in human disease
typically follow three steps: variant calling, where variants in NGS data are iden-
tified, variant annotation, where biologically relevant features are attached to each
variant, and variant interpretation, where statistical and machine learning meth-
ods are used to prioritize putative functional variants. In this thesis, I attempt to
apply and improve these methods in the context of cancer and schizophrenia.
Recent matched tumor/normal whole exome sequencing studies, coupled with
current variant calling tools, have generated large sets of high-confidence genomic
variants. A significant proportion of these variants are missense variants of un-
known impact. To increase the speed and efficiency of annotating these variants,
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I helped in the creation of a database of 86 precomputed disease-relevant fea-
tures for all possible missense variants in the human exome. This tool allows for
near-instantaneous annotation of any variant dataset.
A common limitation of using variant effect prediction software is the limited
ability to infer the actual functional impact of a putative mutation. Most bioinfor-
matics tools will only return a value signifiying the likelihood that the variant is
functional. In an effort to aid in the interpretation of candidate mutations, I cre-
ated a tool capable of mapping one-dimensional sequence positions and features
onto three-dimensional protein positions. Using this database, coupled with an
online web interface, an interactive 3D visualization of the variant position in the
context of its protein is made possible.
I also utilized the NGS variant analysis pipeline to try and uncover novel in-
sights into the genetics of schizophrenia using a matched case/control dataset of
500 postmortem human brain RNA-seq samples. Since RNA-seq is a relatively
new NGS technique, I participated in a study to evaluate its technical repro-
ducibility. As part of this study, I found that a new RNA-seq library preparation
protocol, involving the depletion of ribosomal RNA using magnetic beads, allows
for consistently high detection of intronic reads from pre-mRNAs and of long
noncoding RNAs (lncRNA). To evaulate the role of rare non-coding variants in
schizophrenia, I developed a pipeline for calling rare variants in RNA-seq data,
involving the use of a series of alignment tools, resulting in an 80% decrease in
iii
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the number of false positives as compared to a standard approach. I also created
a pipeline for detecting and analyzing short tandem repeats in RNA-seq data. Us-
ing this pipeline, I discovered statistically significant alterations in intronic short
tandem repeats within genes involved in the innate immune response.
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Chapter 1
Using next-generation sequencing to
probe human genetic variation in
disease
The 21st century is proving to be an exciting time for bioinformatics: Since
2001, the amount of genomic data continues to rise exponentially, doubling every
seven months — outpacing even Moore’s Law [1]. This explosion of data, cou-
pled with the continuously falling cost of computing, is paving the way for the
development of new methods for detecting and analysing genetic (and genomic)
signatures, which in turn allows for the generation of novel insights into human
health and disease.
Disease is an unfortunate aspect of the human condition, and can be classified
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into three parts: Infectious, environmental, and non-communicable. Infectious
disease arises as a result of a transmissable pathogen; environmental diseases are
a product of exposure to a toxin or poison. Non-communicable disease (NCD) is
the global leading cause of death, responsible for 68% of all deaths in 2012 [2].
Almost all non-communicable diseases have a genetic aspect that either directly
leads to illness or modulates an individual’s predisposition towards illness. Iden-
tifying the underlying genetic variations is therefore a key component in uncov-
ering the etiology of NCDs.
Sequencing is a powerful tool for identifying the primary structure (the nu-
cleotides) of DNA or RNA sequences. Due to recent advances in sequencing
technology, it is now possible to obtain a large subset of all genomic variants in a
given genome, using suitable bioinformatics methods.1
This thesis will go over some of the efforts in the development of methods for
analyzing genetic variants in next-generation sequencing data from cancer and
schizophrenia. Chapter 1 will briefly go over the different types of genetic vari-
ation, next-generation sequencing, and the challenges of integrating data science
with bioinformatics. Chapter 2 will discuss some of the basics of calling rare
variants in NGS data, analysis of the feasibility of using RNA-seq data (including
assessments on the reproducibility of RNA-seq), and will go over a bioinformatics
1Some types of variants are easier to detect than others, and the type of sequencing performed
will also influence the kinds of variants that can be detected. This will be discussed in more detail
in a later chapter.
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pipeline I created in an attempt to call rare variants in RNA-seq data. Chapter
3 will provide a short overview of the genetics of cancer, and some heuristics I
generated in an effort to characterize genes in cancer and human disease. Chapter
4 is adapted from a manuscript I co-wrote describing a database of pre-computed
cancer-related features in the human exome. Chapter 5 is adapted from another
manuscript I co-wrote of a database for mapping positions and features from 1D
sequence space onto 3D protein structures. Chapter 6 provides an overview of the
genetics of schizophrenia, and chronicles my attempts to discover genes that may
be enriched for rare variants in schizophrenia. This chapter also goes over some
of the quality control efforts I made when analyzing the RNA-seq data. In chapter
7, I explore the possible effects of short tandem repeats in schizophrenia, trying
to see if there are statistically significant alterations in short tandem repeats in
a schizophrenic population. I also delineate a computational pipeline for calling
short tandem repeats in RNA-seq data. Chapter 8 discusses potential future work
and ideas.
1.1 Human genetic variation
Humans, like all organisms, possess a large spectrum of genetic differences.
Due to the stochastic nature of DNA duplication, even monozygotic (“identical”)
twins are genetically distinct from each other [3]. In this section, I will go through
3
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a brief overview of the human genome and outline the different mechanisms of
genetic variation.
1.1.1 The human genome
The human genome consists of 22 pairs of autosomes2, and a pair of sex chro-
mosomes. The autosomes are numbered from 1 to 22, in rough order of length,
and the sex chromosomes are referred to as “X” and “Y”. In total, the haploid
human genome consists of around 3.2 billion base pairs [4].
The human exome is the most extensively studied subset of the human genome,
consisting of around 20, 000 protein-coding genes and comprising about 1% of the
human genome [5]. Due to alternative splicing, each gene can encode for several
alternative transcripts. To date, there are approximately 80,000 identified protein-
coding transcripts [6].
The existence of non-coding genes has been established for decades, but the
prevalence of non-coding RNAs (ncRNA) in the human genome has only been re-
cently established through the study of the transcriptome [7–9]. To date, there are
approximately 25,000 non-coding genes, but this number is expected to change,
as the functionality of the majority of these putative genes have yet to be deter-
mined [10].
2Autosomes are chromosomes that are not allosomes, or sex chromosomes
4
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1.1.2 Types of variation
The human genome can vary through a variety of mechanisms, ranging from
a single nucleotide change to gross chromosomal rearrangements or deletions. In
this subsection, we’ll go through the different types of variants.
1.1.2.1 Chromosome abnormality
Chromosomal abnormalities are large changes in a section of a chromosome’s
DNA. Aneuploidy is the most dramatic type of chromosomal abnormality, where
either an organism is missing an entire chromosome or has an abnormal number
of duplicate chromosomes. In a diploid organism (such as ourselves), monoploidy
refers to a deletion event (where there is only one copy of a chromosome where
there should be two), and trisomy refers to a single duplication event (where there
are three copies of a chromosome3. Most cases of aneuploidy do not result in
viable offspring, and result from improper cell division during meiosis. The most
common disorder associated with aneuploidy is Down syndrome, which can be
caused by having three copies (trisomy) of chromosome 21 [11].
Besides duplication or deletion of an entire chromosome, sections of a chro-
mosome can also be deleted or duplicated. Translocations can also occur, where
sections of DNA swap between chromosomes. In order to be classified as a chro-
mosomal abnormality, the lengths of these alterations typically need to be at least
3Tetrasomy would refer to four copies.
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a few megabases (Mb) in length, otherwise they are sometimes classified as struc-
tural variations.
1.1.2.2 Structural variation
Structural variations are typically defined as any change in the DNA sequence
of length between one kilobase (Kb, or one thousand bases) to a few megabases.
The most common type of structural variation is copy number variation (CNV),
which involves duplications, deletions, insertions, or translocations of a swath of
DNA. CNVs occur frequently in the human genome, and account for the most
variability in the genome, when counting by base [12].
1.1.2.3 Insertions, deletions, and indels
The terms “insertion” and “deletion” in genetics typically refers to an inser-
tion or deletion of DNA sequence of length 1 to 1000. The term “indel” is a bit
ambiguous, and can either mean “insertion or deletion” or a specific type of vari-
ation where a swath of DNA sequence is first deleted and is then replaced by (via
an insertion) a different DNA sequence. According to the 1,000 Genomes study,
an individual has on average 344,000 insertions & deletions [13]. Due to technical
limitations due to sequencing, this number may be an underestimate [14].
In the context of exome sequencing, with a focus on protein-coding regions of
the genome, insertions and deletions tend to be differentiated into two subtypes:
6
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frameshift and non-frameshift variants. Because translation involves codons of
three nucleotides, an insertion or deletion that does not have a length that is a
multiple of three will result in a shift in the subsequent coding alphabet, leading
to a dramatic change in the amino acid output (and hence, a frameshift). Such
changes do not occur when the length change is a multiple of 3, which will merely
remove or insert amino acids.
1.1.2.4 Single nucleotide variant
Single nucleotide variants (SNVs) are the most prevalent type of variation in
the human genome. SNVs can be divided into separate categories, depending
on their minor allele frequency (MAF). SNVs that occur in more than 1% of the
population tend to be considered common, and are often categorized as single
nucleotide polymorphisms (SNPs). An average individual has about 3.6 million
SNPs in their genome [13]. The number of “rare” SNVs (of minor allele frequency
less than 1%) is still yet to be confidently determined, but I estimate this value to
be no more than 300,000 per individual genome, based on original research.
Most variant prioritization tools have been focused on SNVs, and for good
reason. SNVs are relatively easier to characterize than indels, and often times are
easier to detect compared to structural variants.
7
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1.1.2.5 Variable number tandem repeat
A variable number tandem repeat (VNTR) is composed of a DNA motif that
is repeated a number of times in the genome. VNTRs are usually split into two
categories, microsatellites and minisatellites. Microsatellites, also known as short
tandem repeats (STRs), are comprised of motifs of lengths 1-6 base pairs, re-
peated anywhere between 5-50 times. Minisatellites have larger motifs, usually
between 6-100 base pairs. There are approximately 700,000 STRs in the human
genome [15].
1.2 Next-generation sequencing
Thanks to recent advances in sequencing, it is now possible to get a compre-
hensive readout of many types of genetic variations in a given genome. In order
to understand some of the principles of detecting variants in next-gen sequencing
(NGS) data, an understanding of the principles behind NGS is required. This
section will provide a brief primer of NGS, and of the different types of NGS
methods available.
The fundamental principle behind next-gen sequencing (NGS) is the same as
shotgun sequencing: high-throughput parallel sequencing of random, short seg-
ments of the genome of interest. The main innovation driving NGS involves the
“high-throughput” part — figuring out the DNA sequence of a massive number
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of small fragments at the same time (in parallel). Different NGS technologies
achieve this step through different means.
For Illumina sequencers, high-throughput sequencing is achieved through a
method called “sequencing by synthesis.” Sequence fragments are attached to
the surface of a microfluidic “flow cell,” and fluorescently-labeled nucleotides are
allowed to pair themselves to the sequences in a stepwise fashion. During each
step, replication of the sequence is advanced by one nucleotide. Each nucleotide
is ligated with a differently-colored fluorophore4, and a camera takes a picture
each cycle. A flowcell can contain millions of sequences, which then appear as
a constellation of multicolored “dots” on the camera. Since the camera cannot
possibly detect the light coming from just a single sequence, local amplification
of each sequence “island” is achieved through bridge amplification. In this way,
the flowcell has “colonies” of sequences, where each “colony” (or “polony”) is
composed of thousands of identical sequences.
For PacBio sequencers, a nanophotonic chip is used, containing tens of thou-
sands of tiny wells. Each well acts as a zero-mode waveguide, which essentially
focus light into a very small volume. A polymerase enzyme with DNA is affixed
to the bottom of the well, and during synthesis, bases with fluorophores attached
to the phosphate (which allows for the fluorophore to naturally detach from the
DNA), and the resulting light is picked up by the camera in real-time [16].
4Actually, this is no longer the case, since Illumina has now transitioned to two-color chemistry.
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1.3 Genetics of Disease
Genetic disorders are categorized based on the number of genes that con-
tribute to the disorder. The most straightforward-to-characterize disorders are
single gene disorders, where mutations in a single gene are a necessary and suffi-
cient cause to disease. Most mendelian diseases are single gene diseases, and fall
under the following categories:
• Autosomal dominant/recessive. These genetic disorders involve genes in the
autosomes (not chrM, chrX, or chrY). Autosomal recessive diseases require
both genes (in both autosomes) to be mutated, while autosomal dominant
diseases only require a mutation in one gene for the disease to occur.
• X-linked disorders. These disorders involve mutations in the X chromosome.
Since males have only one copy of chrX, and females have two copies, the
inheritance pattern is slightly more complicated than most autosomal domi-
nant/recessive disorders. Most X-linked disorders follow a recessive inheri-
tance pattern, meaning that these disorders tend to be much more prevalent
in males than females (since females would have to carry mutations in both
X chromosomes, while males only need a mutation in the one X chromo-
some).
• Y-linked disorders. These disorders are exceedingly rare, mainly due to the
fact that chrY is an extremely small chromosome, coding for only a handful
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of genes. Y-linked disorders can only be passed from father to son.
• Mitochondrial disorders. These disorders are based on mutations of genes
in the mitochondrial genome (often labeled as “chrM” or “chrMT”). The
mitochondrial genome is a circular genome of 16,569 base pairs [17]. Dis-
eases involving the mitochondrial genome are passed down from mother to
child, since the mitochondria themselves are conferred to the child via the
mother’s ovum.
Disesases that arise from a combination of mutated genes are commonly re-
ferred to as “complex,” or “polygenic” diseases. Most common diseases, such as
heart disease, diabetes, cancer, schizophrenia, bipolar disorder, and major depres-
sive disorders are complex diseases. Since these disorders depend on a variety of
genes, the inheritance pattern is rarely straightforward to determine.
A number of paradigms have been proposed in an attempt to characterize the
genetic etiology of common disease [18]. The most famous of these paradigms
is the common disease-common variant (CD-CV) hypothesis. The CD-CV hy-
pothesis posits that the foundation of common disease lies in the combination of
commonly-occurring genomic variants. The CD-CV hypothesis is what is driv-
ing GWAS (genome-wide association study), where millions of single nucleotide
polymorphisms (SNPs) are polled for each individual. Although GWAS has been
able to uncover many SNPs and genes that contribute to disease, they only seem
to explain a small fraction of the inheritance of common disease — this is called
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the “missing heritability” problem. Several ideas have been put forward to try
and address the missing heritability: Some heritability might be overlooked by
not considering interactions of common variants, and rare variants with high
penetrance will also be overlooked when using GWAS [19,20]. Analyses of famil-
ial studies have often generated rare SNVs and structural variants, which led to
the formulation of the common disease-rare variant (CD-RV) hypothesis — that
a small number of highly-penetrant rare variants affect gene function, leading to
disease.
1.4 Data science and bioinformatics
Traditionally, bioinformatics methods have been limited by the “small n, large
p” problem, where n is the number of samples, and p is the number of “pre-
dictors,” or features in a given sample. A typical example is a microarray study
carried out on a limited number of subjects. Sample size may be extremely small
(n = 30 subjects), but a microarray would generate a large p for each sample
(p = 20, 000 gene expression values). This problem has also been observed in
other fields, such as image analysis, economics, and astronomy [21–23].
The meteoric rise in the amount of genomic information is a product of recent
substantial improvements in sequencing technology. From 2007 to 2012, the cost
of sequencing has fallen by over three orders of magnitude [24]. Due to the
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dramatically lower cost of sequencing, it is now possible to generate “medium n,
large p” datasets, where n is now approaching the same magnitude as p. This
is great news when performing statistical analyses: Increasing the sample size
will improve statistical power, but having datasets of such a magnitude presents
challenges for data storage and organization.
For example, consider a typical case/control study utilizing transcriptomic
data. There are currently 198,619 known, annotated transcripts [10]. If we have
1,000 cases and 1,000 controls, our study will generate 397,238,000 records. If we
store this information into unsorted flat files (text files), it will take forever to try
and search for necessary information.
Fortunately, bioinformatics data is often represented in a tabular format, which
makes it easy to incorporate into a relational database. The dataset will be stored
in a SQL (Structured Query Language) table; singular data records will occupy a
row of the table, and features (or attibutes or fields) will be stored in the columns.
For this example, the table would most likely have columns such as sample id,
transcript id, expression value, and each row would be a single expression
value of a single transcript in a single sample.
Perhaps the most useful aspect of a relational database is the ability to put
constraints on the data. Constraints such as enforcing the expression values to
be non-negative acts to verify the integrity of incoming data. Indexing the data
allows for fast data access, and it is akin to a library creating a card-catalog —
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unlike flat files, where search times follow O (n) time, indexing allows queries to
follow O (log (n)) time.
SQL databases are also easily scalable. The underlying architecture can be
identical for a 10-record database and a 10-billion record database, with no singi-
ficant hit on performance.
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Calling rare variants in RNA-seq data
RNA-seq is traditionally used to quantify the expression of genes and tran-
scripts, identify gene fusion events, and detect instances of RNA editing [25–29].
Since RNA-seq is still fundamentally a sequencing method, it is possible to an-
alyze the read-out of the sequence and look for variants. In this chapter, I will
evaluate the technical reproducibility of RNA-seq, identify potential sources of
bias, go over the typical bioinformatics pipeline for calling rare variants, deter-
mine the fitness of the typical rare-variant calling pipeline on RNA-seq data, and
propose a new method for calling rare variants in RNA-seq data.
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2.1 Evaluation of RNA-seq
Because RNA-seq is a relatively new sequencing technology, it is vital to eval-
uate its technical reproducibility, as well as to identify possible sources of biases.
In order to achieve this objective, we took a standardized sample of RNA, dis-
tributed identical copies of this sample to different sequencing centers, and asked
various groups to sequence multiple technical replicates of the RNA using dif-
ferent sequencing platforms and RNA preparation protocols (Figure 2.1). This
section is based on material from Li et al. 2014 [30].
Figure 2.1: ABRF NGS RNA-seq study design.
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2.1.1 Experimental design
Two separate commercial sets of standardized RNA samples were used in the
study. The first sample, the Universal Human Reference RNA (UHRR), consists
of a mix of total RNA from 10 human cell lines. The second sample, the Human
Brain Reference RNA (HBRR), consists of total RNA from 23 Caucasians, taken
from various regions of the brain. For this study, the UHRR sample was labeled
as sample “A”, and the HBRR sample was labeled as sample “B.” These samples
were previously used in a similar study evaluating the reproducibility of microar-
rays [31]. In addition to the A and B samples, 1:3 and 3:1 mixes of A and B were
also created (labeled as “C” and “D”).
Synthetic RNA of known primary structure and concentrations, developed
by the External RNA Control Consortium, were also “spiked-into” each mix.
These “spike-ins” consist of 92 polyadenylated transcripts, ranging from 250-2000
nucleotides, with a primary sequence designed to be distinct from the human
genome (thus maximizing the chance that a read originating from the ERCC can
be uniquely aligned) [32, 33].
Technical replicates of each A, B, A/B mix were distributed to several se-
quencing centers, and were sequenced on a variety of platforms: Illumina HiSeq
2000/2500, Life Technologies Ion PGM, Roche 454, and Pacific Biosciences (PacBio)
RS. Of particular interest are the reads originating from the Illumina HiSeq 2000/2500,
since the data involved in this text are generated from Illumina machines.
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2.1.1.1 RNA preparation
In order to prepare the RNA for sequencing on the HiSeq 2000/2500, two
different library preparation protocols were followed. The first protocol used
the Illumina TruSeq Library Preparation Kit, which selects for polyadenylated
transripts. The second protocol used the Illumina TruSeq Library Preparation
Kit, paired with the Epicentre Biolotechnologies Ribo-Zero Gold system, which
removes ribosomal and mitochondrial RNA.
2.1.1.2 Sequencing
After the DNA was confirmed to be of sufficient quality by Bioanalyzer anal-
ysis, the completed libraries were attached with barcodes, multiplexed to 12 sam-
ples per lane, and distributed across channels on three different flow cells, in
order to account for variability due to lane number and run sequence. Paired-end
2x50bp reads were generated for each run, the raw BCL (base call) files were then
demultiplexed, converted to fastq, and then distributed to the members of the
consortium.
2.1.2 Bioinformatics
Quality control (QC) information was first generated on the fastq reads using
fastQC [34]. The raw fastq reads were then aligned to the hg19 (GRCh37) hu-
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man assembly using the STAR aligner [35]. With the resulting BAM files, gene
expression values (FPKMs) were generated using htseq-count [36].
2.1.2.1 RNA-seq quantification metrics
For subsequent downstream analysis of gene quantification, FPKM values
were used, which stand for “Fragments per kilobase of exon per million mapped
reads.” In this segment we will define this, and other similar quantification met-
rics.
The RPKM/FPKM metric (reads/fragments per kilobase of exon per million
mapped reads) was designed to account for a length bias in the number of reads
that map to a transcript/gene of interest. Given m genes/transcripts, the RPKM









where C is the number of reads (counts), and L̃ is the effective length of the
gene/transcript of interest, which is defined as
L̃ = L   µL + 1 (2.2)
where L is the length of the gene/transcript of interest, and µL is the mean
read/fragment length. The effective length is used since the number of possi-
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ble positions a read can map to a gene/transcript depends on the length of the
read, as well as the length of the transcript.
For example, take the string “ABCDEF.” If we are sequencing reads of length
3 from this string, there are 6   3 + 1 = 4 possible reads that map to “ABCDEF”:
“ABC,” “BCD,” “CDE,” and “DEF.”





For paired-end reads, a similar metric, the FPKM (fragments per kilobase of
exon per million mapped reads) is used, which treats each read of a pair sepa-
rately. In short, for single-end reads, the RPKM metric is used, and for paired-end
reads, FPKM is the metric to use.
Due to some criticism of the RPKM/FPKM metric’s inconsistency when com-
paring across samples, the transcripts per million (TPM) metric has gained some











CA 106 . (2.4)
The TPM has an added benefit of being easily interpretable; TPMi is the num-
ber of transcripts one would expect to see for transcript i when one randomly
sequences 1 million transcripts from the sample.
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2.1.2.2 Between-sample vs. Within-sample normalization
The above defined metrics, the RPKM/FPKM and TPM, are an attempt to nor-
malize the expression values within a given sample. Unfortunately, these metrics
tend to have difficulty comparing expression between distinct samples [39,40]. In
order to successfully compare expression samples, between-sample normalization
methods have been developed — the most popular methods are Trimmed Mean
of M values (TMM), and the DESeq normalization package [41, 42].
2.1.2.3 Differential expression analysis
In order to perform differential expression analysis on the technical repli-
cates, raw counts were normalized using the Trimmed Mean of M values (TMM)
method [42].
2.1.2.4 RNA QC collection
In order to calculate more RNA-seq QC metrics downstream from alignment,
the RSeQC package was used to calculate metrics such as the genebody coverage,
read distribution, duplication rate, and the chrM read proportion [43]. RSeQC
takes in a sorted, indexed BAM file, and returns a folder of metrics, depending
on the type of test desired.
21
CHAPTER 2. CALLING RARE VARIANTS IN RNA-SEQ DATA
2.1.2.5 Variability of RNA-seq transcript quantification
In order to assess the variability in transcript expression values compared
across technical replicates and across sequencing platforms, the coefficient of vari-
ation was calculated for each normalized transcript count. The coefficient of vari-





For empirical data, the coefficient of variation can be estimated using the sam-





When comparing between platforms, the Illumina HiSeq generates the lowest
median inter-site variation (Figure 2.2). This low degree of variation exhibited
by Illumina data is also demonstrated when comparing the Spearman correlation
(0.98 for all samples of “A”, and 0.99 for all samples of “B”). Due to the extremely
high number of reads generated, the HiSeq also demonstrates the highest level of
sensitivity when detecting genes. Unfortunately, due to the extremely short read
length (50bp in this study), the junction detection rate is lower than that of other
platforms. A separate study has verified that increased read length significantly
improves junction detection (leading to better assembly accuracy), but that single-
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Figure 2.2: Variation metrics of normalized transcript quantification, evaluated
within and between sequencing platforms. (a) Between-site coefficient of variation
(CV) of normalized transcript expression values, evaluated across all sites. (b)
Intra- and inter- platform Spearman correlation coefficients for samples A and
B. (c) CV of samples matched against degraded RNA samples. (d,e) Number of
detected genes & junctions against number of bases sequenced. (f) Average read
length improves junction detection rate. Illumina has the shortest read length
(50bp), and PacBio has the longest read length (several kilobases). (g) Already
annotated junctions are picked up more reliably than “novel” junctions.
end 50bp reads are sufficient for performing differential expression analyses [44].
When comparing identical RNA samples enriched through Poly-A and Ri-
boZero, there is a reasonably high degree of correlation of expression values,
with Spearman correlations ranging between 0.91 and 0.93.
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2.1.2.6 Read distribution
RSeQC was used to determine the percentage of reads mapping to various
gene regions [43]. When comparing Illumina RNA samples that were prepared
by poly-A pulldown vs. RiboZero, we noticed significantly more intronic reads
coming from the RiboZero data (Figure 2.3). This is due to unspliced pre-mRNA
reads originating from the nucleus [45, 46]. There is also an uptick in the number
of ribosomal RNA detected in the RiboZero data, whereas the PolyA data has
virtually no ribosomal reads. This will be an important factor to consider for
RiboZero data; filtering out rRNA reads will be necessary to have comparable
expression values downstream, especially if the rRNA read proportion is greater
than 1%.
2.2 Standard pipeline for calling rare vari-
ants in NGS data
The previous section went over the technical reproducibility of RNA-seq data,
as well as some of the differences between Poly-A and RiboZero libraries. In
this section, I will go over the typical bioinformatics tools used to ascertain rare
variants from raw NGS data.
When calling variants from NGS data, whole genome sequencing (WGS) or
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Figure 2.3: Distribution of Illumina reads mapping to different gene regions, from
reads coming from Poly-A enriched samples and RiboZero depleted samples.
whole exome sequencing (WES) data is typically used. Due to the significant cost
savings of WES (as compared to WGS), if variants in coding regions are of primary
interest, then whole exome sequencing is the traditional tool to use. However,
recent research has challenged this prevailing line of thought [47]. Coding SNVs
seem to be well-detected using both methods, but CNVs remain a challenge for
WES.
The type of technical considerations that need addressing will depend on the
type of variant one is interested in calling:
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1. Structural variants. The detection of structural variants (SVs) relies on the
existence of three types of reads:
(a) Depth of coverage. For WGS and WES data, CNVs can be detected by
finding regions of unusually high or low coverage.
(b) Split reads. A read that, when split, maps to two disjoint genomic re-
gions, could be an indication of a SV.
(c) Discordant read pair. A paired-end read, where each mate maps to vastly
distant regions of the genome, can also be an indication of a SV.
2. Small insertions/deletions, and SNVs. To check the veracity of a candidate
insertion/deletion or SNVs, there must be sufficient coverage of the region
of interest to make sure that the putative variant is not a false positive that
may have arisen due to a single read’s sequencing error, or perhaps due to
mistakes during PCR (polymerase chain reaction).
3. Variable number tandem repeats. In order to determine the full length of a
VNTR, the sequencer must be able to generate reads that can fully span the
length of the repeat, as well as its flanking region. The length of the se-
quenced flanking region(s) must be sufficiently long enough to be uniquely
mappable to the reference genome. Technical errors must also be taken into
account, as the rate of variation of a VNTR is many orders of magnitude
higher than that of any other variant type [48–50]. For paired-end reads, it
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may be possible to determine the STR length if the STR happens to span
both mates, and the length of the fragment is known.
In order to limit the scope of this thesis, we will shift our focus towards calling
STRs, short insertions/deletions, and SNVs. But before I completely abandon
SVs, a few remarks about calling structural variants using RNA-seq:
1. CNVs will be extremely difficult to detect in RNA-seq data, as these may be
indistinguishable from simple over/under-expression.
2. Gene fusion events can definitely be detected using RNA-seq, and RNA-seq
may possibly be an ideal tool for detecting fusions.
3. There are aligners that are tailored for RNA-seq reads, that can also detect
chimeric reads (reads mapping to separate places in the genome). TopHat
& STAR are two such aligners that come to mind.
2.2.1 Bioinformatics pipeline for calling rare variants
This subsection will go through the typical software used to process rare vari-
ants from raw NGS data. In short, the pipeline is as follows: QC, alignment,
more QC, variant calling, variant filtering, variant annotation, variant interpreta-
tion/prioritization.
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2.2.1.1 Raw fastq quality control
Before performing variant calling (or any sort of bioinformatics analysis), we
need to make sure that the raw fastq files coming out of the sequencing machines
meet certain quality standards. FastQC is the tool of choice, which is a java
program that runs a battery of QC checks on the fastq file [34]. The following is a
list of commonly-encountered considerations when dealing with non-ideal fastqc
files:
• Adapter sequences. Adapter sequences are usually trimmed prior to prepa-
ration of the fastq file. If this step was not performed correctly, adapter
sequences in the fastq files may be misconstrued as false insertions or false
SNVs.
• Low base quality. Each nucleotide in a fastq file has a corresponding quality
score, which reports the likelihood of the particular base being called incor-
rectly [51]. This “phred” score Q is defined as Q =  10 log10 P, where P
is the probability of an incorrect base call. A phred score of Q = 40 would
then mean an error probability of P = 10  40/10 = 10 4 = 1/10000. Low phred
scores will result in false positive variant calls. For Illumina sequencing
data, the base quality scores often take a dive near the end of the sequence,
so care must be taken when calling variants from the ends of a read. If the
quality scores near the read ends are too low (Q < 25 is a rule of thumb), it
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may be advisable to trim the ends of the reads.
• Duplication rate. For RNA-seq data, it is natural to have some duplicated
reads due to highly expressed genes. If the number of duplicated reads
is inordinately high, say, greater than 10%, then this could be a sign of a
serious PCR amplification artifact.
2.2.1.2 Read alignment
Once the fastq files have been confirmed to be of sufficient quality, the next
step in the bioinformatics pipeline is to align the reads to a reference genome.
In other words, we need to know where in the genome a read maps to. For hu-
man fastq files, the typical reference is either hg19 (GRCh37) or hg38 (GRCh38).
These represent the “standardized” haploid sequences of all human chromo-
somes. Hg19/hg38 does not represent an actual human individual, it is an at-
tempt to “average out” the variation of a diverse population of human genomes.
This is, of course, an imperfect process, so what is considered a “variant” when
called against hg19/hg38 may actually be the most prevalent allele in the popu-
lation.
For WGS and WES, there are several aligners that are capable of mapping
reads to a reference in a very short amount of time, compared to traditional align-
ers such as Smith-Waterman, Needleman-Wunsch, BLAST, and BLAT. Bowtie and
BWA are the two most commonly-used aligners to date.
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For RNA-seq reads, performing high-quality alignments is significantly more
difficult than aligning short reads from WGS and WES data, due to the fact that
there will be reads that span exon-intron junctions. To an unprepared aligner,
these will look like giant deletions, and indeed, most WES/WGS aligners make a
key assumption that most reads will be contiguously mappable to the reference
genome. TopHat is a popular RNA-seq aligner, but STAR is beginning to become
quite prominent as well, due to its significantly faster rate of alignment [35, 52].
2.2.1.3 BAM file QC
Once fastq reads have been mapped to a human reference, the typical output
is a Sequence Alignment Map (SAM) file. In practice, the BAM file, a compressed
version of the SAM file, is stored after alignment.
Once the BAM file is generated, we can run RSeQC, samtools flagstat, and the
aligner QC reports, to assess other quality control metrics:
• Mapping rate. If an inordinate proportion of reads are not mappable to the
reference genome (below 80% is a rule of thumb), this is a red flag, and
could indicate the following problems:
1. RNA/DNA contamination from another species
2. Enrichment of reads of extremely low quality, rendering them unmap-
pable
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3. Reads dominated by adapter sequences
4. Reads originating from regions of the reference genome that are not
uniquely mappable
• Proportion of reads originating from chrM. An overabundance of reads origi-
nating from the mitochondrial genome may indicate severe degradation of
the sample of interest, or a failure of library construction.
• Proportion of rRNA reads. Unique to RNA-seq, an overabundance of riboso-
mal reads may also indicate a failure of library construction, or a sign of a
severely degraded sample, where only rRNA is present.
2.2.1.4 BAM file processing
Once the BAM file has been sorted and indexed, which is typically done with
samtools, additional processing needs to take place, depending on the type of se-
quencing. For exome and WGS data, in order to minimize the impact of PCR
amplification errors, duplicate reads need to be removed from the BAM file. sam-
tools rmdup or Picard are tools that are capable of flagging and removing duplicate
reads.
For calling short insertions, deletions, and indels, it may also be preferable
to re-align reads with putative insertions/deletions/indels, as some of these can-
didate variants may be simply false positives arising from misalignment. Local
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alignment is also preferable when one is interested in SNVs that occur near in-
dels, since a falsely called indel can also result in false positive SNVs being called
nearby. The IndelRealigner tool from the Genome Analysis Toolkit (GATK) is one
such tool for realigning indels.
2.2.1.5 Variant calling
With the BAM file properly processed, we can use variant calling software to
get a list of putative variants [53]. For exome and WGS data, the most popular
tools are as follows:
• Samtools mpileup. The first variant caller that gained widespread use, mpileup
is relatively fast and efficient, but the false positive filters are a bit primitive
and the threshold for calling variants is quite optimistic, leading to great
sensitivity, but lower specificity, especially when calling indels [54].
• Genome Analysis Toolkit’s UnifiedGenotyper & HaplotypeCaller. Genome Anal-
ysis Toolkit (GATK) is currently considered the golden standard for vari-
ant calling. GATK’s UnifiedGenotyper uses a Bayesian model, whereas the
GATK HaplotypeCaller first re-assembles the candidate variant region to
determine candidate haplotypes, re-aligns using Smith-Waterman, then de-
termines the likelihood of a particular haplotype by performing a pairwise
alignment of reads against each candidate haplotype. Genotypes are then
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calculated by selecting the alleles with the highest likelihoods (given each
haplotype). Currently, GATK recommends the use of HaplotypeCaller over
UnifiedGenotyper [55].
• Freebayes. Freebayes is another haplotype-based variant calling tool, where
haplotypes are estimated with a Bayesian approach. Freebayes is capable
of phasing, modeling multiallelic loci, handling non-diploid organisms, and
can detect complex multinucleotide variants (MNVs) [56].
• Platypus. Platypus is another variant caller that also calls variants using local
assembly, realignment, and haplotype estimation using a Bayesian model.
The main advantage of Platypus is the fact that it is at least 10 times faster
than other variant callers [57].
2.2.1.6 Variant filtering
Once a candidate variant is called, various filtering steps must be followed in
order to make sure the variant is not a false positive. Ideally, variant calling is
an extremely easy task — simply find areas that mismatch against the reference.
Unfortunately, the majority of such mismatches are due to false positives.
There are two approaches to dealing with false positives. One is to incorporate
the false positive likelihoods into an already existing Bayesian model. Another is
to use a battery of simple heuristic cut-offs that, in an ideal situation, can perfectly
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separate false positives from true positives.
The following is a list of features that are taken into consideration when de-
termining a variant’s chance of being a false positive:
• Base quality. False positives tend to have lower base quality scores.
• Unmapped mate. A well-behaving paired-end read would ideally have both
mates mapped to the same general location. If only one mate is mappable,
that could be an indication of an improperly mapped read — that is, a read
that shouldn’t be mapped.
• Strand bias. A true, well-behaving variant should be invariant towards read
strandedness; it should not matter which way the read goes, the variant
should exist in both directions. A strong bias towards one strand could be a
sign of an improper alignment.
• Allele bias. For a diploid organism, a variant should be either homozygous
or heterozygous for an allele — that is, have exactly zero, one, or two copies
of the alternative allele. Therefore, the proportion of reads containing alter-
native allele and the reference allele should ideally be 0%, 50%, or 100%.
• Positional bias. For a true variant, there should be no bias in the position of
the detected variant inside the read. For example, if all the reads supporting
a putative variant have the putative variant near the end of the read, this
could be a sign of improper alignment — meaning that only reads of that
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particular orientation are mapped to the putative region, resulting in a false
positive call.
• Mismatch bias. It is unusual to encounter large clusters of variants in the
same place (or in the same read), unless the read is improperly mapped,
and generates several spurious mismatches.
These features are included in almost all variant calling tools, so manual vari-
ant filtering is not usually carried out. That being said, it is still important to
be familiar with these features, since you can tweak the cutoffs to best suit your
experiment, when running the variant calling tools. For example, if you have can-
cer data that has matched tumor/normal samples, and you are only interested in
somatic mutations, having an initial high false positive rate might be acceptable,
since you have the matched normal sample to nullify any false positives. On the
other hand, if you are running a large case/control study, you might be willing to
sacrifice sensitivity for specificity - in which case, you would run the caller with
more stringent parameters.
2.2.1.7 Variant annotation
After running a variant caller, and getting a list of vetted, putative variants,
these variants are usually stored in a Variant Call Format (VCF) file. A VCF file is
a tab-delimited file that contains basic variant information, such as the chromo-
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somal position, reference and alternative allele, and other optional information
that is dependent on the variant caller used — such as depth of coverage, allele
frequency, and quality score. [58, 59].
Before performing the actual variant annotation, additional VCF processing
steps might be necessary. Two popular tools for processing VCF files are vcftools,
vcflib, and GATK [55,58,60]. The following is a list of common VCF parsing steps:
• VCF filtering. Depending on the type of VCF caller, a variant that fails fil-
tering will have the failure mode flagged in the “FILTER” field, instead of
being removed from the VCF file outright. For downstream annotation and
analysis, it is often preferable to have these completely removed from the
VCF.
• Masking. Masking areas of the genome, and “blacklisting,” or removing all
candidate variants that occur in these regions, is a common step in parsing
VCF files. The most common type of mask is removing variants in very low
entropy regions (such as areas annotated by repeatmasker [61].
• Breaking or creating multiallelic variants. Depending on the variant caller or
the variant annotator used, it may be desirable to either re-create a previ-
ously broken multiallelic variant into a single line, or to create separate VCF
records for multiallelic variants. It may also be desirable to only focus on
the most common allele.
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• Breaking or creating multinucleotide variants. Also dependent on the variant
caller & annotator chosen, you may also wish to consider breaking up MNVs
into adjacent SNVs, or joining adjacent SNVs into a single MNV record.
• Left aligning indels & complex variants. Most, but not all, variant callers will
left-align variants. Since there are multiple ways to represent an indel, left-
aligning an indel (changing its start and stop position to be closest to the
5’ end of a chromosome) is critical, since having multiple representations of
the same variant will make downstream indel comparisons almost impossi-
ble [62].
• VCF sorting and indexing. If the VCF file is extremely large in size, some
downstream tools will enjoy a performance boost if the VCF is sorted and
indexed.
With a properly parsed VCF file, the next step is to annotate the variants, and
attach a battery of features in order to get a better understanding of the variant
in question. The most popular tool in use for variant annotation is ANNOVAR,
but there are also other tools that are gaining popularity, such as GEMINI and
VAT [63–65].
The following is a list of the most common annotations attached to variants:
• Gene. When doing downstream analyis, it is often critical to know which
variants occur in which gene. If the variants are in intergenic regions, they
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are often removed from further analysis.
• Gene substructure. If you are dealing with whole exome sequencing data, you
are most likely interested only in variants in coding regions. If the variants
are annotated to occur in untranslated (UTR) regions or introns, they may
also be removed from further analysis.
• Amino acid change. When prioritizing variants in coding regions, it is often
necessary to also know if there are any changes to the amino acid sequence.
If there is no change (a synonymous variant), these variants may also be
removed.
• Conservation. If a variant occurs in a highly conserved region, that might
increase the chance of the variant negatively affecting downstream function.
• Functional annotation. Conservation is just one of a large variety of features
that attempt to assess the functionality of a given genetic region. If one is in-
terested in epigenetics, CpG islands may be of interest. If you are interested
in alternative splicing, annotation of splicing motifs may be useful.
If calling rare variants is of primary interest, it is at this step where you would
determine whether a called variant is known to be common, and thus would filter
them out. Databases such as dbSNP, variants from 1,000 genomes, HapMap, are
useful for identifying common variants.
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2.2.1.8 Variant interpretation
Attached with an informative set of features, machine learning methods can be
used to predict what, if any, impact the variant will have on protein or transcript
function. Currently, most software packages are focused on predicting the impact
of missense variants on protein function. The most well-known packages that do
this are SIFT, Polyphen, SnpEff, and Variant Effect Predictor (VEP) [66–69]. There
are also newer packages that are gaining in popularity: Variant Annotation, Anal-
ysis, and Search Tool (VAAST) and Functional Analysis through Hidden Markov
Models (FATHMM) [68, 70].
2.3 Unique strengths & challenges when us-
ing RNA-seq data to detect genomic vari-
ants
RNA-seq is primarily a tool for transcriptome characterization, but the raw
data coming from the sequencer can still be used to call genomic variants. Call-
ing variants using RNA-seq offers a couple of unique advantages over more tra-
ditional NGS methods:
1. Coverage of non-coding regions. Exome sequencing is designed to capture only
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the coding region of the human genome, leaving out possibly interesting re-
gions such as introns, UTRs, and previously unannotated non-coding RNAs.
RNA-seq is capable of sequencing pre-mRNAs that have yet to have their
introns fully spliced out.
2. Cheaper than whole-genome sequencing. Using high-coverage RNA-seq could
be a decent compromise between cost and sensitivity when it comes to
detecting non-coding genomic regions. With unlimited resources, whole
genome sequencing (WGS) would be the ideal tool to use for calling non-
coding variants, since it is unbiased in terms of the genomic region being
sequenced. This absence of bias also is the reason behind its high cost, since
many reads will be wasted sequencing uninteresting intergenic portions of
the genome.
Before one goes about calling variants in RNA-seq, several challenges unique
to RNA-seq data must be addressed:
1. Non-uniform coverage. RNA-seq is a functional read-out of the transcrip-
tome. Therefore, genes that are not currently being transcribed will not
be detectable in the RNA-seq data. Genes that are lowly expressed will
also face difficulty in sequencing, therefore reducing the sensitivity of any
downstream variant caller.
2. Spliced reads. RNA-seq will contain reads that span exons (and thus skip-
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ping the intron). To an unprepared variant caller, this may look like a giant
deletion.
3. RNA editing. RNA editing will be detectable in RNA-seq data, and to a
sequencing machine, these events will be indistinguishable from SNVs.
In order to adapt standard rare-variant calling practices on RNA-seq data, I
decided to make the following changes:
1. Split spliced reads. By convention, an RNA-seq aligner will flag spliced reads
with an “N” in the CIGAR value, which is a string (in a SAM/BAM file)
that summarizes the read alignment against the reference genome. Variant
callers are unable to deal with “N” CIGAR values, and sometimes treat
them as unacceptably long indels (and therefore discard these information-
containing reads). To get around this issue, I used the tool SplitNCigarReads
from GATK and splitNReads from Miika Ahdesmaki [55, 71].
2. Remove RNA editing sites. Once candidate variants are called and placed
in a VCF file, I created a mask around known and predicted RNA-editing
sites from the RADAR and DARNED databases [72, 73]. With this mask, I
removed all putative rare variants that overlap with these positions.
In the following subsection, I will outline in detail the steps and packages I
used to assemble the first prototype of the rare variant calling pipeline for RNA-
seq.
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2.3.1 Rare variant calling pipeline for RNA-seq, in de-
tail
First, the raw fastq files were quality checked using fastQC. The quality-
checked fastq files were then aligned to hg19 with GENCODE gene annotations
(version 19). STAR aligner was used to align the reads. I chose STAR over other,
possibly more accurate aligners, such as TopHat & GSNAP, due to STAR’s over-
whelming performance advantage: STAR is approximately 150 times faster than
TopHat (and GSNAP is slower than TopHat).
Once the BAM files are generated, I sorted and indexed the files using sam-
tools. To take care of the split reads, I used GATK’s SplitNCigarReads to divide up
junction-spanning reads. I then used GATK HaplotypeCaller to make the variant
calls. On later runs, I also used freebayes and Platypus to call variants.
With the generated VCF files, I filtered out regions overlapping repeatmasker
regions and RNA-editing sites predicted by RADAR and DARNED. The remain-
ing variants were annotated by ANNOVAR, and common variants with a minor
allele frequency > 1% occurring in 1000 genomes, the exome sequencing project
(ESP6500), the exome aggregation consortium (ExAC), and Complete Genomics
(CG46), were filtered out.
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2.4 Evaluation of rare-variant calling pipeline
on exemplary data
When inventing a new computational pipeline, it is advisable to evaluate the
pipeline on a set of exemplary data, in order to measure valuable performance
metrics such as the sensitivity and specificity. Here is a quick overview of some
performance terms:
• Sensitivity, or the true positive rate, or recall, is the ratio of the number of
samples identified as positive, divided by the total number of true positives.
• Specificity, or the true negative rate, is the ratio of the number of samples
identified as negative, divided by the total number of true negatives.
In other words, sensitivity is a measure of how well a classifier can pick out
true positives. Specificity is a measure of how well a classifier can avoid false
positives.
I used the Genome in a Bottle (GIAB) consortium’s extensively verified set
of variants in sample NA12878 as the exemplary dataset for rare variant call-
ing [74]. In the GIAB study, a human volunteer had her genome sequenced using
extremely deep whole genome sequencing, using 5 different sequencers, 7 differ-
ent aligners, and 3 different variant callers. A list of concordant genotypes was
generated, with a corresponding BED file reporting confidently called regions.
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In order to compare the RNA-seq rare variant calling pipeline with the GIAB
dataset, I used publicly-available RNA-seq data of the same individual (NA12878),
made available by the ENCODE consortium, sequenced on an older Illumina
Genome Analyzer IIx (GAIIx), generating 2x76bp paired-end reads [75].
I called rare variants on this ENCODE RNA-seq dataset, and compared those
against the exemplar variants detected by the GIAB consortium. The subsequent
analysis generated surprising results — most of the putative rare variants called
by a typical naı̈ve variant calling pipeline generated a significant number of false
positives. In fact, the number of false positives outnumbered the number of true
positives. I observed similar results when calling variants using freebayes and
Platypus. I also observed similar false positive rates when using a separate RNA-
seq dataset (of NA12878).
The extremely high false positive rate is disturbing, but after more consid-
eration (and some extensive literature review), seems plausible. Variant callers,
when assessing performance, often combine common and rare variants together,
making the assumption that the sensitivity and specificity of detecting common
variants and rare variants are identical. Unfortunately, I believe that conflating the
two variant types is dangerous when assessing rare variant calling performance.
If a false positive call is made, what is the likelihood that it just happens to occur
at a SNP? It will most likely be a unique false positive, and therefore be classified
as a rare variant. A typical individual has approximately 3.5 million SNPs [13].
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Individual NA12878, sequenced by GIAB, has 303,583 rare variants. Since the
number of SNPs outnumber rare variants by an order of magnitude, conflating
common and rare variants will generate an overly-optimistic estimation of the
false positive rate, when calling rare variants.
2.5 Analysis of putative rare variants confirmed
to be false positives
To gain a better understanding of the mechanisms behind the false positives,
I used the Integrated Genomics Viewer (IGV) to open up the BAM files and vi-
sualize the reads that contribute to a given false positive [76]. IGV is a great way
to visualize the distribution of reads mapping to a chromosomal region of inter-
est. By default, any mismatches from the reference genome will be highlighted,
low quality bases will be flagged (and greyed-out), and a histogram represent-
ing the depth of coverage at each base will be shown above the visualization
of reads. I also mapped suspect reads against BLAT to determine the level of
misalignment [77]. BLAT is capable of handling spilced reads, and has excellent
sensitivity, and therefore can come up with a comprehensive list of alignment
alternatives.
After manual inspection of over 500 false positives, I determined that most
false positives arise from the following factors:
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1. Misalignment. Re-alignment of a suspect read, using BLAT, reveals a better,
mismatch-free alignment for the candidate read.
2. Low base quality. Consistently low base quality scores in the candidate region
correlate with false positives.
3. Soft clipped reads. Aligners will often soft-clip reads with unsatisfactory
alignment near the ends of a read. Soft-clipping is different from hard-
clipping in that the sequence is preserved, but flagged (with a “S” in the
CIGAR field). Sometimes, the aligner is not parsimonious enough with the
soft-clipping, and permits low-quality regions to persist in the read.
4. Homopolymer run. A homopolymer run is a sequence of the same consecu-
tive bases (for example, “AAAAAAAAAA”). Due to the extremely unstable
nature of these runs, it is commonplace to observe expansions and contrac-
tions of these regions.
We can also see that these sources of error are also the underlying factors
behind many of the features used to model false positives in variant calling tools.
Table 2.1 gives a rundown of the underlying causes behind each false positive
filter.
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Table 2.1: False positive filters and their underlying causes.
False positive filter Underlying cause
Base quality bias Low base quality
Duplicated reads Low base quality
Unmapped mate bias Misalignment
Strand bias Misalignment
Allele bias Misalignment, RNA-editing
Positional bias Misalignment
Mismatch bias Misalignment, low base quality
Homopolymer region Homopolymer expansion/contraction
2.6 Development of a new RNA-seq rare vari-
ant calling pipeline
With the drivers behind rare variant false positives in mind, I decided to come
up with a new, more stringent rare variant calling pipeline that addresses each of
the four main challenges.
1. Remove soft-clipped reads. Instead of trying to estimate how much of a soft-
clipped read to trust, I simply eliminated all reads with a soft-clipped region
from further analysis.
2. Enact stricter base quality cutoffs. In order to tackle false positives arising
from lousy base quality, I tuned the variant caller to be more stringent when
considering low quality bases.
3. Mask homopolymer regions. I created a BED (browser extensible data) contain-
ins all known homopolymer repeat regions in the genome. With this mask,
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I removed all variants overlapping these regions.
4. Re-align all reads containing a putative rare variant. Using a BED file con-
taining the loci of all putative rare variants, extract a subset of the original
BAM file (using samtools), containing only reads overlapping these candi-
date regions. Convert these reads back to FASTQ format, and re-align using
GSNAP [78]. GSNAP is much slower than STAR, but is considered one of
the most accurate spliced-read aligners.
5. Remove putative variants in genomic regions that cannot be uniquly mapped. To
minimize the chance of any possible misalignment, I also made sure that
each candidate rare variant appears in a genomic region that can be uniquely
mapped to the reference genome. To this end, I took a window of sequence
upstream and downstream of the variant in question (for example, ±50 bp),
and aligned this sequence to the reference genome using BLAT. If there
are many candidate hits elsewhere in the genome that are almost perfect
matches to the queried sequence, I remove the variant from further analysis.
Misalignment is the dominant factor behind most false positives when calling
RNA-seq rare variants. This is the reason why I decided to use three aligners
as part of the new pipeline. I’m currently calling this pipeline the “three-pass”
pipeline, but perhaps in the future I’ll come up with a more clever name.
Most variant calling pipelines would not attempt to use STAR and GSNAP, and
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BLAT is almost out of the question. On an average computer, STAR can process
about 5,000 reads per second, GSNAP can process about 300 reads per second,
and BLAT processes about 50 reads per second. Due to my large sample size, and
limited computational resources, I decided to first align the reads using STAR
(due to its exceptional speed), collect all putative rare variants, extract only the
reads overlapping candidate variant regions (cutting down the size of the fastq
file by at least a factor of 10, up to 100), re-align the reads using GSNAP, re-
run the variant caller, find a new set of candidate variant regions, and determine
the region’s mappability using BLAT. Figure 2.4 outlines the software pipeline in
more detail.
Figure 2.4: Software pipeline for confident calling of rare variants in RNA-seq
data.
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I first take the raw fastq files and align them to the hg19 human reference an-
notated with GENCODE version 19 gene annotations. I then sort and index the
resulting BAM file using samtools. With the sorted file, I use GATK’s SplitNCi-
garReads to split up junction-spanning reads. I re-sort and re-index with samtools,
and then run Platypus to get an initial set of candidate variants. With the resulting
VCF file, I remove RNA-editing instances using a BED file containing previously-
discovered RNA-editing sites from RADAR and DARNED. I also remove variants
in homopolymer regions with a BED file containing all known homopolymer run
sites in hg19 (as discovered by repeatmasker). These removal steps are done with
with the vcffilter tool in VCFtools. I then convert the final VCF file into an input
format compatible with ANNOVAR (using one of annovar’s scripts), and then
run ANNOVAR, removing common variants with minor allele frequency > 1%
in any observed subpopulation. The output is then converted into a BED file of
all putative rare variants.
With this BED file, I use samtools to extract reads overlapping candidate rare
variant regions. These reads are converted into FASTQ format, and then re-
aligned to hg19 (with GENCODE V19 annotations) using GSNAP. Duplicates are
then marked using Picard MarkDuplicates. The reads are again split using GATK’s
SplitNCigarReads, and Platypus is again used to call the variants.
For each candidate variant in the VCF file, the genomic sequence surrounding
the variant of interest is extracted from the hg19 reference and converted into a
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FASTA file. These sequences are then aligned by BLAT against hg19. Candidate
regions that have alternative mapping sites with a quality score difference less
than 2 are removed. In other words, if the region around a candidate rare variant
can be mapped to another region of hg19 with almost equal mapping score, the
variant is thrown out as a possible false positive. After this final step, the list of
final candidates is outputted as a tab delimited file.
2.7 Evaluation of new RNA-seq rare variant
calling pipeline
In order to evaluate the performance of this new “three-pass” pipeline, I ran
the pipeline on the same data I used to evaluate the “regular” rare variant call-
ing pipeline (the GIAB NA12878 WGS data and the ENCODE NA12878 RNA-seq
data). The three-pass pipeline, compared to the standard pipeline, has signifi-
cantly fewer false positives, cutting down the false positive rate from approxi-
mately 50% to about 5%. This reduction comes at a significant hit to sensitivity;
about 50% fewer rare variants are called using the three-pass method.
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Genomic landscape of cancer
The previous chapter discussed some of the methods behind calling rare vari-
ants. In this chapter, I will go over some of the practical applications of calling
variants, in relation to the field of cancer research. Before I do so, I will briefly go
over some of the key concepts of cancer, discuss general categories of variants in
cancer, and go over some of the simple heuristics that can evaluate a gene’s role
in cancer.
3.1 Tumor suppressors & oncogenes
Cancer is, at its core, a disease caused by the regulatory breakdown of cellular
growth. There are many mechanisms that can be perturbed that can lead to this
breakdown, such as amplification of growth signals, resistance to anti-growth reg-
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ulators, resistance to programmed cell death (apoptosis), resistance to senescence,
upregulated angiogenesis, development of metastatic behavior, evasion of the im-
mune system, activation of chronic inflammation, and deregulation of metabolic
pathways [79, 80].
Genes that contribute to cancer can be roughly placed into two categories: tu-
mor suppressors and oncogenes. These two categories are often analogized as
“brake pedals” and “gas pedals.” Tumor suppressors restrict cellular growth,
acting as checkpoints during cellular replication, detecting and repairing DNA
damage, and promoting apoptosis [81]. Oncogenes typically involve genes that
promote cellular growth, including transcription factors, growth factors, growth
factor receptors, chromatin remodelers, signal transducers, and apoptotic regula-
tors [82].
3.2 Drivers and passengers
Alterations in the DNA of a normal cell is what causes a normally-functioning
gene to transform into a knocked-out tumor suppressor or a functional oncogene.
Because a tumor suppressor gene acts to prevent cancer progression, mutations in
these genes tend to “knock-out” gene function. Often times, even a single func-
tioning copy of the gene is still functional enough to prevent cancer progression,
hence the formation of the “two-hit hypothesis,” that both copies of the gene need
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to be knocked-out in order to be cancer-promoting [83].
Because oncogenes act to accelerate cancer progression, causative mutations in
proto-oncogenes do not need to occur in both alleles, since a single affected copy
will be sufficient in promoting cellular growth. Therefore, mutations in oncogenes
tend to be “activating” or “gain-of-function” mutations, either by increasing pro-
tein expression, or by altering protein function (for example, by making a growth
factor receptor constitutively active).
The car analogy can be extended to cover this phenomenon: Imagine a car
with two brakes and two gas pedals (humans being a diploid organism). The
car will still be stoppable with one failed brake pedal, as long as the other one
still functions. However, the car only needs one gas pedal to be stuck in order to
accelerate uncontrollably.
According to the Cancer Gene Census, over 1% of all genes are implicated
in cancer [84]. Of the 572 genes currently implicated in cancer, about 90% have
cataloged somatic mutations, 20% have known germline mutations, and 10% have
both somatic and germline mutations [85].
There are a wide variety of cancer-promoting variants (driver mutations); they
range from gross chromosomal changes to single point mutations. Approximately
95% of driver mutations are SNVs [86]. According to the Catalogue of Somatic
Mutations in Cancer (COSMIC) version v70, there are approximately 2 million
coding point mutations, 10,500 gene fusions, 60,000 genomic rearrangements, and
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695,000 abnormal CNVs [87]. There may be a bias towards detection of coding
missense mutations (due to an emphasis on exome sequencing), similar to the ob-
servational bias towards detecting massive exoplanets by using the transit method
or the radial velocity method [88].
3.3 Development of a simple heuristic for
classifying tumor suppressors & oncogenes
In order to gain a better understanding of which genes act as tumor suppres-
sors, and which genes act as oncogenes, I worked with Dr. Bert Vogelstein to
develop a simple metric for classifying genes in the Catalogue of Somatic Mu-
tations in Cancer (COSMIC). Vogelstein noticed two key observations regarding
COSMIC genes:
• Mutation clustering in oncogenes. For genes previously implicated as onco-
genes, missense mutations tend to exhibit a large degree of positional clus-
tering. For example, for KRAS, over 99% of cancer somatic mutations in
KRAS are missense mutations, and almost exclusively affect residues 12 and
13 (Figure 3.1).
• Enrichment for loss-of-function mutations in tumor suppressors. For genes pre-
viously identified as tumor suppressors, there is a significantly higher pro-
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portion of loss-of-function mutations. For example, over 90% of all cancer
mutations observed in APC are either nonsense mutations or frameshift mu-
tations (Figure 3.2).
Figure 3.1: Histogram of KRAS missense mutations in COSMIC. Figure generated
from the COSMIC website [89].
Figure 3.2: Distribution of mutation types of APC in COSMIC. Figure generated
from the COSMIC website [89].
With these two key observations, Vogelstein and I created a simple decision-
tree for classifying genes in COSMIC. For genes with more than 5 records in
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COSMIC, if more than 15% of all records affect the same residue (and thus ev-
idence of clustering), we classify that gene as an oncogene. If more than 15%
of all records are loss-of-function mutations (frameshift or nonsense mutations),
we classify the gene as a tumor suppressor (Figure 3.3). I named this heuristic
“BUSDrivers,” short for “Bert’s Updating Selection of Drivers”.
Figure 3.3: Decision tree for classifying genes in COSMIC.
Using BUSdrivers, we are able to correctly categorize many of the commonly-
known tumor suppresors and oncogenes. BRAF, KRAS, EGRF, KIT, PIK3CA, and
IDH1 are among the list of correctly-identified oncogenes. APC, NF2, WT1, and
RB1 are among the list of correctly-identified tumor suppressors.
We also noticed a number of genes that fulfilled both conditions; more than
15% of mutations occur in the same amino acid, and greater than 15% of mu-
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tations are inactivating. Among the list of genes that fulfill both these criteria
are TP53, PTEN, VHL, NOTCH1, CDKN2A, FBXW7, RUNX1, and ATM. Most
of these genes are typically considered tumor suppressors, but they also harbor
gain-of-function mutations that act in a dominant negative fashion [90–95]. In
other words, these point mutations are “so bad,” they interfere with the normal
functioning copy, subverting the two-hit hypothesis and making the tumor sup-
pressor behave like an oncogene (in that it only required a single gain-of-function
mutation in one allele).
3.4 Detection of different clustering signa-
tures in genes implicated in autosomal
dominant and autosomal recessive dis-
eases
One of the main observations from the previous section is that in oncogenes,
cancer-promoting mutations tend to be gain-of-function mutations, and they ex-
hibit tight positional clustering. We wanted to extend this hypothesis, and see if
genes implicated in autosomal dominant mendelian diseases might also present
tight clustering of rare missense mutations. This section is based on material from
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Turner et al. 2015 [96].
For autosomal dominant (AD) mendelian disease, only one copy of an affected
allele needs to exist in order for disease to occur. This is in contrast to autosomal
recessive (AR) mendelian disease, where a hit has to occur in both alleles. With
this in mind, we wanted to explore whether AD and AR disease-related genes
have missense mutational distributions similar to oncogenes and tumor suppres-
sors. For an AD gene enriched with gain-of-function (GOF) missense mutations,
we would expect these mutations to cluster around functional regions. For an
(AR) gene, we may also expect loss-of-function (LOF) missense mutations to pref-
erentially occur in functional regions.
We define clustering as missense mutation positions in a given gene occurring
closer to each other (in the primary sequence) than would be observed by chance.
In order to quantify clustering, I define a new, unbiased metric, CLUstering of
Mutation Positions (CLUMP), which applies the Partitioning Around Medoids
(PAM) clustering algorithm to a list of integer-indexed amino acid residue posi-
tions [97]. We use the pamk implementation of PAM fpc package in R. The number
of clusters k is not specified in advance, but is estimated by varying k over multi-
ple PAM runs and selecting k⇤ that yields the maximum average silhouette width.
Thus, both the number of clusters and a “medoid,” or representative member of
each cluster are estimated by the algorithm. Next, for each cluster i, we compute
the distance between each member of the cluster and its medoid and take a log
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sum of these distances over all clusters. The final CLUMP score Sp for a given














where Xij is the position of mutation j in cluster i, mi is the position of the medoid
of cluster i, ni is the number of mutations in cluster i, and k⇤ is the total number
of clusters in the gene. The maximum clustering possible is when all observed
mutations in all clusters occur in the same position as the cluster medoid, yielding
a score of 0. In general, a protein with highly-localized mutations will have a low
CLUMP score, while a protein with mutations spread across its protein sequence
will have a high score.
To assess the statistical significance of Sp, we calculate a CLUMP score for all
disease-associated missense mutations in a gene, and a separate CLUMP score
for missense variants from 1000 genomes. Disease-associated missense mutations
were taken from the Human Gene Mutation Database version 2014.2. To deter-
mine whether a gene is associated with AD or AR disease, we parsed abstracts in
PubMed, looking for the keywords “autosomal dominant” or “autosomal reces-
sive.” We also filtered out any pubmed entries with an association to cancer, as we
were only interested in mendelian disease. In order to get a high-confidence set
of gene/disease associations, we disregarded genes with fewer than 12 publica-
tions, and required greater than 75% consensus towards AD/AR assignment. The
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remaining 706 gene/disease associations were then manually checked for correct
assignment using OMIM and primary literature search.
Using the Wilcoxon rank sum test, we find that proteins with AD mutations
exhibited tighter clustering compared to 1000 genome variants (P = 3.1 ⇥ 10 12),
and compared to AR proteins (P = 8.4 ⇥ 10 4). We also observe that AR proteins
exhibit more localization than 1000 genomes as well (P = 0.03). A cumulative
distribution plot of the CLUMP scores can be seen in Figure 3.4.
Figure 3.4: Cumulative distributions of CLUMP scores per gene
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3.5 Classification of novel missense mutations
in cancer
Cancer cells tend to accumulate many variants over time, but only a fraction
of these variants will be cancer promoting. [98, 99]. Variants that promote tumor
growth are classified as “drivers,” while neutral variations that are just “along for
the ride” are classified as “passengers.” Determining whether a given variant is a
driver or a passenger is an ongoing challenge.
Some types of variants are easier to classify than others. A stop mutation or
a frameshift mutation has obvious impacts on the functionality of a gene. If the
gene is previously known to be a tumor suppressor, we can safely assume an
obvious loss-of-function mutation to be a driver.
Unfortunately, the majority of somatic mutations in cancer are single nu-
cleotide variants, leading to missense variations in the amino acid sequence. De-
termining the functional impact of a single amino acid change is a much harder
problem to solve.
With a good training set of known driver mutations and known passengers,
supervised machine learning algorithms can be used to predict the functionality
of a previously unencountered somatic missense variation. The most popular tool
for classifying somatic missense mutations in cancer is CHASM, short for Cancer-
specific High-Throughput Annotation of Somatic Mutations [100]. CHASM uses a
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random forest trained on 3,299 driver missense mutations from COSMIC, curated
by Bert Vogelstein, and a set of 4,500 synthetically-generated passenger muta-
tions. The passenger mutations are generated by modeling the tumor mutation
background using the dinucleotide contexts. For each mutation, a set of 70+ fea-
tures are annotated, ranging from features such as multiple sequence alignment
(MSA) entropy, to amino acid changes (e.g., change in hydrophobicity), to exonic
SNP density. The random forest uses an ensemble of decision trees, each trained
on a random sampling of the data and the features. To evaluate a novel missense
variant, each tree in the forest casts a “vote,” as to whether the features in the




cancer-related features in the human
exome
For the purposes of illustration, let us assume we wish to create a machine
learning algorithm that can, whenever we take a photo, recognize whether the
image contains a cat. The performance of such an algorithm (and all supervised
machine learning algorithms), depends on the following factors:
• Clean training data. Care must be taken to ensure that the labels for each
training datapoint are correctly assigned. If 10% of our training data cat
pictures are actually pictures of dogs, then our classifier is no longer a “cat
pic” classifier, it becomes a “fairly good cat, but occasionally a dog” pic
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classifier.
• Training data is a representative sampling of data to be evaluated. It is critical to
have a clear understanding of which data are in the “positive” class, and
which kind of data are in the “negative” class. If our positive training data
are pictures of cats, and our negative training data pictures of dogs, then
our classifier is meaningless if we present it with ostrich pictures for classi-
fication.
• Informative features. Feature engineering is crucial for good classifier per-
formance. Although most classifiers have some degree of robustness when
it comes to ignoring useless features, there must at least be a handful of
truly informative features that can discriminate between the classes. Fea-
tures such as the timestamp (when the photo was taken), intensity of the
17th pixel, number of legs, would probably be useless when it comes to
evaluating cat and dog pictures.
In the last section of the previous chapter, I went over some of the basic work-
ings of CHASM, a random forest classifier trained to discriminate driver mu-
tations from passengers. Some of the key aspects behind CHASM are its 70+
features used to annotate a candidate missense variant.
Feature annotation tends to be the most time- and data-intensive steps when
using machine learning. In this chapter I will go over some of our work involving
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a database of pre-computed features covering all possible nucleotide changes in
the annotated human exome. This database can either be used in a stand-alone
fashion, or as part of a larger variant discovery / variant annotation pipeline. This
chapter is based on material from Wong et al. 2011 [101].
SNVBox, the name of our precomputed feature database, is a MySQL database
of 86 predictive features relevant to the biological impact of a SNV. The features
have been pre-computed for each codon in all protein-coding exons of anno-
tated human mRNA transcripts in the NCBI RefSeq, CCDS, and EBI Ensembl
databases [102–104]. A visualization of the database schema can be seen in Figure
4.1, and a description of available tables in the SNVBox database is shown in Ta-
ble 4.1. The SnvGet program, included as part of the SNVBox package, allows for
fast retrieval of selected features from the SNVBox database for classifier training
and for scoring of mutations inputted by the user.
SNVBox comes packaged with CHASM, which is an open-sourced collection
of Python and C++ programs that can take a list of somatic missense mutations
as input and rank them according to their likely tumorigenic impact. Users have
the option to use their own estimates of passenger variant frequencies to generate
synthetic passenger mutations, or select from a library of pre-generated passenger
frequency tables derived from several common cancers.
PyInstaller version 1.4 was used to package the Python source code into dy-
namically linked, executable binaries. The SnvGet, BuildClassifier, and RunChasm
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executables are run by the user on the command line. The statically-compiled
C++ executable waffles learn from the WAFFLES machine learning library is also
used internally.
4.1 Program workflow
1. Prepare an input file of estimated passenger mutation rates in the cancer of
interest. Optionally, select from one of several pre-computed passenger rate
tables.
2. Prepare an input file of missense SNVs to be classified. Each row contains a
protein accession identifier, codon number, and reference and variant amino
acid residues.
3. Run the BuildClassifier program.
• BuildClassifier generates in silico passenger mutations by introduc-
ing random nucleotide substitutions in a sequence library of expressed
human mRNA transcripts from NCBI RefSeq, according to the distri-
butions specified by the passenger mutation rate table.
• BuildClassifier fetches a list of predictive features for each variant in
the training set from SNVBox.
• BuildClassifier then trains the random forest classifier using waffles learn.
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4. Execute the RunChasm program.
• RunChasm retrieves features from SNVBox, for all inputted variants.
• CHASM then scores each candidate variant supplied by the user.
• A second set of passenger variants are generated, filtering out variants
in genes that have been previously implicated in cancer. These genes
are taken from COSMIC, the Cancer Gene Census, and all cancer gene-
sets in MSigDB [84, 105].
• These filtered passengers are then scored by CHASM, generating an
empirical null of variant scores.
• This null distribution is then used to calculate the P-value for each
user-submitted variant (by calculating the fraction of the null distribu-
tion having CHASM scores equal to or more extreme than the variant
CHASM score).
• The P-values are then adjusted using the Benjamini-Hochberg multiple
testing correction [106].
• A tab-separated list of user-supplied variants, CHASM scores, P-values,
and Benjamini-Hochberg estimated false discovery rate (FDR) is finally
outputted.
• An attribute-relation file format (ARFF) file is also outputted, contain-
ing model data in a format optimized for some machine learning pack-
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ages.
Figure 4.1: SNVBox database schema.
4.2 SNVBox discussion
The CHASM/SNVBox toolkit is the first distributable software package that
specifically targets somatic missense mutations in cancer. The random forest clas-
sifier in CHASM is tuned to discriminate between known drivers and a set of
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Table 4.1: Description of tables in SNVBox.
SNVBox Table Description Example features
AA features Amino acid substitution fea-
tures.
Volume change, hydrophobicity
change, frequency of change in
COSMIC
Exon features Exon conservation and variabil-
ity
46-way exon conservation, SNP
density
Features Metadata table of features SNVBox feature name, table
name, column name
Genomic MSA 46-way vertebrate conservation Relative entropy, absolute en-
tropy, PHC scores
Local Structure Predicted protein structure Stability, predicted helix, pre-
dicted coil, solvent accessibility
Regional Comp Regional amino acid composi-
tion
Proportion of glycines, prolines,
AA entropy
Sam MSA Conservation calculated with
SAM-t2k HMM MSA
Entropy, relative entropy, PHC
scores
Transcript mRNA accession IDs in CCDS,
RefSeq, and Ensembl
RefSeq transcript ID, RefSeq
protein ID, CCDS accession
Transcript Exon Exon boundaries in each mRNA
transcript
Exon ID, chromosome, start,
stop, direction of transcription
Triplet Features Triplet AA frequencies calcu-
lated by SwissProt
First position probability, sec-
ond position probability
Uniprot Xref Cross-reference mapping pro-
tein position to UniProt position
Protein ID, protein position,
UniProt ID, UniProt position
Uniprot Features Protein features derived from
Uniprot
Binding site, active site, metal
binding site, disulfide bridge,
zinc finger region
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synthetically generated passenger mutations that match the mutational spectrum
of the cancer of interest. CHASM results are sensitive to this mutational spectrum,
and users are encouraged to use the somatic variant calls from their sequencing
data to create the best possible estimate of the mutational spectrum.
While many SNV classifiers are available via web interfaces, these tools are
not capable of handling large input datasets (e.g., thousands to millions of SNVs
discovered through high-throughput sequencing projects). Researchers have de-
veloped distributable packages that users can run on their local system to en-
able high-throughput SNV processing. These packages depend on third-party
databases (sequences, alignments, protein structures, specialized protein anno-
tations) and third-party software packages. The popular PolyPhen package, for
example, requires installation of 10 third-party software packages, in addition
to three Perl modules. To our knowledge, all available SNV classification tools
must calculate or retrieve features “on-the-fly,” almost always using third-party
databases and software in the process. In contrast, the predictive features avail-
able in SNVBox (also calculated by third-party tools) have been exhaustively
pre-computed, allowing rapid retrieval for any given custom dataset. In bench-
mark testing, retrieval of 86 features for one million SNVs took 11.39h on a Dell
R900 server with two AMD Opteron dual-core 64-bit CPUs with 16GB of RAM.
CHASM score computation for these one million SNVs took an additional 10m
and 33s.
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Finally, the predictive features available in SNVBox have been designed to be
useful for classification of both germline and somatic SNVs. We hope that SNV




Database mapping positions &
features from 1D sequence position
to 3D protein structure
With the advent of cheap next-gen sequencing, it is now possible to execute
large-scale studies generating millions of SNVs of interest. Bioinformatic meth-
ods have been developed to predict a given SNV’s impact on protein function,
allowing for downstream prioritization of high-scoring SNVs. Interpreting a high-
scoring SNV’s impact on actual protein structure or function remains a challenge.
One approach for interpreting SNV function is to map the SNV onto the three-
dimensional protein structure in which it occurs.
Working with SNVs in the three-dimensional context of the protein confers
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two advantages:
• Variant interpretability. By being able to visualize the variant in the context of
the 3D protein environment, we can more easily create hypotheses on how
the SNV affects protein function or structure.
• More informative distance metric. Proteins are three-dimensional creatures.
What may be distant in one-dimensional sequence space may be extremely
close in three-dimensional space due to protein folding. A more meaningful
distance metric will make downstream analysis more accurate, especially
when trying to quantify clustering.
In this chapter, I will go over the details of a database I created that maps
1D sequence position (and relevant features) to available 3D protein structures.
We named this tool MuPIT-DB (Mutation Position Imaging Tool Database). This
chapter is based on material from Niknafs et al. 2013 [107].
The MuPIT database is the back-end to the MuPIT visualization tool, a web-
server written in Java. The Java servlet encapsulates a series of Django appli-
cations: A Jmol applet for 3D protein visualization, a database (DB) interfacer
accessing the MuPIT DB, and an overview page constructor [108]. Javascript func-
tions are used to allow for user interactions between the overview tables and the
3D visualization.
The MuPIT database contains mappings from genomic coordinates to PDB
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structure coordinates, using methods developed in the LS-SNP/PDB applica-
tion [109]. In brief, a software pipeline uses BLAT to align protein sequences from
Protein Data Bank (PDB) structures to human protein sequences in the UniProt
knowledgebase (UniProtKDB) [77, 110, 111]. UniProtKB protein sequences are
aligned to RefSeq mRNA transcript sequences with tBLASTn, and mRNA tran-
script sequences are aligned to human genomic DNA with BLAT [112]. Currently,
only the canonical isoform of each UniProtKB protein sequence is supported. PDB
sequence is taken from a local mirror of the PDB database [110]. The UniProt
sequences and feature annotations are taken from a local mirror of the UniPro-
tKB [111]. Alignments are calculated on a high-performance computing cluster,
managed by the Son of Grid Engine (SGE) batch-queuing system. The resulting
annotations and alignments are stored in a MySQL database, which is updated
on a monthly basis to ensure synchrony with its external sources.
5.1 Coverage
MuPIT currently provides at least one viewable PDB structure for 3,641 hu-
man proteins (which is 18% of the 20,226 SwissProt-curated proteins in UniPro-
tKB), and covers 924,857 codons in protein-coding exons (which is 8.2% of the
11,291,814 total codons in SwissProt). Coverage of cancer-related genes is some-
what higher: 45% of 487 genes in the Cancer Gene Census (March 2012 ver-
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sion) and 16% of the codons in these genes are covered in the current version of
MuPIT [84].
5.2 Database pipeline
The Mupit DB can be divided into three main parts:
1. Database of aligned SwissProt position to PDB position,
2. Database of aligned PDB position to genomic coordinate,
3. Database of features mapped to PDB position.
5.2.1 SwissProt to PDB alignment
The SwissProt-to-PDB alignment begins by calling helper functions to fetch the
relevant SwissProt and PDB sequences. Pairwise alignment is done using BLAT,
and the resulting PSL file is then evaluated using a Python script (filterPSL). If
the alignment is not redundant and of sufficient quality, the PSL is stored into
the MySQL database (into the table Sprot2PDBAlign), and positional mappings are
calculated using another helper function (pdb2sprot). These mappings are then
placed into the Sprot2PDB MySQL table (Figure 5.1).
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Figure 5.1: Detailed flowchart for mapping SwissProt sequences to PDB sequence.
5.2.2 PDB to genomic coordinates
In order to convert PDB positions to chromosomal coordinates, we first map
the SwissProt sequences onto RefSeq, and then fetch the RefSeq-to-genome align-
ments. The SwissProt/RefSeq alignments are done using the script sprot2Refseq,
which is a wrapper around tBLASTn, taking in a protein sequence, and mapping
them onto matching nucleotide sequences. The resulting blastXml file is then con-
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verted into a PSL file, and filtered using filterPSL. Any alignments that pass the
filter are then stored into the Sprot2RefseqAlign table. RefSeq-to-genome align-
ments are fetched using the refSeqGet tool from the Kent source utilities, and then
placed into the Refseq2GenomeAlign table [113]. Once the alignment tables are in
place, another python helper function genome2pdbMap is used to get the final PDB
to genome mappings, which are then placed into the Genome2PDB MySQL table.
5.3 Mapping SwissProt features onto PDB struc-
tures
Once the Sprot2PDB table has finished populating, we can use this table to map
the SwissProt features (which populate the SwissProt Features table) onto match-
ing PDBs. The helper function sprot features full will execute the mappings,
and place the results into PDB Features.
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Analysis of rare variants in
schizophrenia
6.1 Genetics of schizophrenia
Schizophrenia is one of the most prevalent psychiatric disorders, presenting a
lifetime risk of 0.7% worldwide [114]. Genetics have been shown to be the most
dominant risk factor behind schizophrenia; twin and family studies have shown
a heritability of ⇠ 70%, one of the highest among psychiatric diseases [115–117].
In spite of the high heritability, the genetic mechanisms driving schizophrenia are
still unclear.
Several large-scale studies have been developed to determine whether schizophre-
nia falls under a set of commonly-encountered genetic paradigms. Because schizophre-
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nia is a relatively common disease, genome-wide association studies (GWAS) have
been carried out to determine whether the common disease-common variant hy-
pothesis explains schizophrenia [118–121]. GWAS studies have discovered many
significant SNPs and implicated several genes, but they have not discovered any
“smoking guns.” There doesn’t seem to be any single SNP, or group of SNPs, that
can fully account for schizophrenia. S. Hong Lee et al. have estimated that SNPs
account for 23% of variation in liability to schizophrenia [122].
Another popular paradigm is the common disease-rare variant hypothesis
(CDRV). A small set of highly penetrant rare variants may affect one or more
genes, leading to disease. Rare variants are typically defined as a variant with
a minor allele frequency less than 0.5% or 1%. Several whole exome sequenc-
ing studies on schizophrenia have suggested a polygenic burden of rare variants
implicated in schizophrenia, but with the possible exception of TAF13, no sin-
gle gene is shown to be significantly enriched in rare variants in schizophren-
ics [123–126].
In light of these promising results from GWAS and exome sequencing studies,
a common reaction is to increase the sample size in the hopes of uncovering more
causative genes/variants leading to schizophrenia. This is an effort to increase
statistical power. Statistical power is defined to be the probability of rejecting the
null hypothesis H0 provided that the alternative hypothesis H1 is actually true.
There are five main factors that influence statistical power:
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• Measurement error. Increasing precision (reducing the measurement error)
for each sample reduces the variance, making it easier to discriminate a
bimodal distribution.
• Effect size. A large effect size (e.g., standardized mean difference between
two populations) usually leads to an increased distance between peaks of a
bimodal distribution, also facilitating discrimination.
• P-value cutoff. The significance cutoff controls the a, the type I error, and
changing this cutoff also indirectly influences the type II error (b), which is
the complement of power (1   b).
• Study design. Focusing on samples lying on the extreme ends of a distribu-
tion of interest, or relying on a family with multiple affected phenotypes can
increase the likelihood of discovering significance.
• Sample size. Increasing the sample size creates a better estimate of the popu-
lation distribution, increasing the likelihood of discovering small differences
between distributions.
Conducting future studies of identical design with increased sample size is
a double-edged sword. Statistical power will be increased, but often with a hit
to the effect size of observed significant results. If there is a gene/variant with
a huge effect size, there would be no need to conduct a larger study, since pre-
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vious studies with smaller sample sizes should have been able to detect these
results [127, 128].
6.2 Non-coding rare variants
In light of the observations made from previous GWAS and whole exome se-
quencing studies, I wanted to see if it was possible to examine areas of the genome
that were previously overlooked. GWAS can pick up common variants in coding,
noncoding, and intergenic regions. Exome sequencing studies are primarily fo-
cused on coding variants. In this section, I will go over some of the reasoning
behind looking for rare variants in noncoding regions.
Once overlooked in favor of protein-coding genes, non-coding RNA (ncRNA)
have started to enter the research limelight, thanks to recent whole transcrip-
tome sequencing efforts that highlight the ubiquity of noncoding RNA in the
genome [129]. Non-coding RNAs have also been implicated in brain develop-
ment, synaptic plasticity, and psychiatric disease [130, 131]. The long non-coding
RNA (lncRNA) Gomafu has been shown to be dysregulated in schizophrenia [132].
Introns have also been overlooked in the past, thought to be little more than
a transcriptional speedbump on the path to a translated protein. Due to the fact
that most introns are spliced out of the final transcript, it can be easy to assume
that most introns would have little to no effect on gene function. The following is
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a list of the ways an intron can affect gene function; this list is taken from Chorev
et al. 2012 [133]:
• Transcription initiation. Enhancers and silencers in the 5’-most intron can
regulate transcription initiation. Alternative promoters can also initiate tran-
scription in a separate downstream location from the canonical transcription
start site.
• Genes inside introns. Also called nested genes, these are transcripts that reside
completely within the intron of a larger, encapsulating gene.
• Delay of transcription. Extremely long introns increase the overall length of
transcription, causing the polymerase to take up to several extra hours to
fully transcribe the gene.
• Alternative splicing. Splicing regulatory elements (SREs) are motifs inside
the pre-mRNA of interest that recruit splicing factors that either enhance or
silence alternative splicing. Such elements inside an exon are called exonic
splicing enhancers and exonic splicing silencers (ESEs and ESSes), and such
elements inside introns are called intronic splicing enhancers and intronic
splicing silencers (ISEs and ISSes).
• Nonsense mediated decay (NMD). After splicing, an exon-junction complex
(EJC) persists in the pre-mRNA, which acts as a signpost of past splicing.
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Existence of EJCs significantly downstream from the stop codon triggers
NMD.
• Cytoplasmic localization. EJCs also seem to play a role in cytoplasmic localiza-
tion. For example, alternative isoforms of BDNF determine whether BDNF
localizes in the dendrites or the soma of a neuron [134].
• Intron retention. Considered the least prevalent form of alternative splicing
in mammals, a recent paper has shown possible evidence of widespread
intron retention in human and mouse poly-A RNA-seq data [135].
• Recursive splicing. Instead of being removed as a single unit, long introns that
contain recursive splice sites (RS-sites) allow for multiple splicing events to
remove the long intron iteratively. In vertebrates, long introns contain a
small recursive splicing exon (RS-exon) that allows for recursive splicing to
occur. These RS-exons may remain in the final spliced product, affecting
mRNA function [136].
Introns may be of particular interest in psychiatric disease. Brain-specific genes
are longer in length, and tend to contain extremely long introns [137]. Brain-
specific genes also seem to have developed mechanisms for regulating long genes;
the gene MECP2 represses long genes by binding to methylated CA regions; dis-
ruptions in the MECP2 gene lead to Rett syndrome [138]. The gene TDP-43 is
involved in alternative splicing regulation, and has been shown to sustain and
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upregulate long pre-mRNAs by binding to GU-rich intronic sites; disruptions in
this gene have been implicated in amyotrophic lateral sclerosis [139].
The different intronic effects on gene function also rely on different aspects
of the intron. Some effects, such as those relying on the EJC, such as NMD and
localization, depend merely on the existence of an intron, regardless of its length
or sequence. Transcriptional delay mechanisms depend on the length of the intron
— the longer the intron, the longer it takes for polymerase to transcribe [140].
Of special interest are the intronic regulators that depend on the actual intronic
sequence. Intronic enhancers & silencers, intron retention, recursive splicing, and
alternative splicing all can be pertubed by intronic variants. By using a deep
neural network, Xiong et al. were able to establish that intronic variants can impact
splicing performance; by applying their method to a whole-genome sequencing
case/control dataset of autism, they demonstrated that most of the high-scoring
variants are intronic [141].
In light of these observations of non-coding RNA and introns affecting neu-
ronal regulation and neurological disorders, I thought it would be worthwhile
to examine these regions in a case/control study of schizophrenia, since these
regions have been overlooked in previous studies.
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6.3 RNA-seq dataset
In order to poll the non-coding regions of the genome, I relied on Ribo-
depleted (RiboZero Gold) RNA-seq data, which we have shown in a previous
chapter to contain many reads mapping to intronic regions, and are capable of
detecting noncoding RNA with higher sensitivity than poly-A RNA-seq.
Table 6.1 contains the number of post-mortem brain RNA-seq samples used in
this chapter. Due to the low number of asian and hispanic samples, these samples
were removed from further analysis.
Table 6.1: Number of control and schizophrenic RNA-seq postmortem brain sam-
ples.
Race Condition Number of samples
African american Control 180Schizophrenic 85
Asian american Control 6Schizophrenic 3
Caucasian Control 133Schizophrenic 81
Hispanic Control 9Schizophrenic 3
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6.4 Quality-control analysis of RNA-seq sam-
ples
Before we do any serious analysis of the RNA-seq samples, it is important to
determine if there are any samples that have quality control metric outliers — in-
cluding these samples in downstream analysis might introduce unnecessary false
positives, or decrease statistical power (due to the samples being too lousy for
any sort of genomic variation detection). The dataset in Table 6.1 was chosen af-
ter manual curation of fastQC results. FastQC is not the be-all, end-all solution for
QC, unfortunately. Read aligners also generate QC reports, with metrics such as
proportion of successfully mapped reads, proportion of reads that are spliced, etc. RSeQC
is also used to generate QC metrics of generated BAM files. In this section, I use
both of these QC reports to look for any possible outliers or systematic biases in
the RNA-seq data.
The STAR aligner was used to align reads to the GENCODE V19 annotated
hg19 human reference [6, 35]. The proportion of reads successfully mapping to
the GENCODE V19 hg19 was taken from the STAR QC logs. RSeQC was used to
determine the proportion of reads mapping to the mitochondrial genome (chrM)
and the proportion of ribosomal RNA (rRNA) reads [43].
The RNA integrity number (RIN) is a commonly-used metric for RNA qual-
ity. Before the introduction of the RIN value, RNA quality was often estimated
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by considering the ratio of 28S and 18S ribosomal RNA, since 28S rRNA tend
to degrade more quickly than 18S rRNA. This method has been shown to be in-
consistent [142]. The RIN value incorporates several other features, including the
ratio of 18S/28S reads vs all reads and the total amount of 28S reads. For this
chapter, the RIN values were generated by an Agilent Bioanalyzer.
Figure 6.1 shows a scatterplot of the pair-wise relationships between the per-
centage of mapped reads (pmappedreads max), the proportion of reads mapping
to the mitochrondrial genome (p chrm), the proportion of ribosomal RNA reads
(p rrna), and the RIN. From this diagram, it is clear that there are a significant
number of outliers. Luckily, there does not seem to be a systematic bias between
cases and controls in any of the metrics. There is a clear relationship between the
total number of mapped reads and the proportion of reads mapping to chrM and
rRNA.
I hope I’m not spoiling the ending here, or ruining the narrative, but in truth,
I actually ran the variant calling pipeline first, without doing this QC first. In
retrospect, I should have filtered out the samples first. In any case, using the
variant calling pipeline, I was able to determine the number of high-confidence
variants called in the data. What made me go back and check the QC results
was the discovery that there were a handful of samples with an alarmingly low
number of detected variants (Figure 6.2).
A usual QC cut-off is to set a threshold on the percentage of mapped reads. For
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this study, I decided on an arbitrary cutoff of 70%, this seems to do a decent job
getting rid of samples that have a pathologically low number of variants called.
6.4.1 Quality control of polyA RNA-seq samples
The previous section covered the QC I did on the RiboZero Gold RNA-seq
samples. We also have a set of polyA RNA-seq samples from the same individu-
als, and I figured I might as well run a similar QC check on these samples, in case
we wished to use this dataset for downstream analysis.
After selecting samples that passed fastQC checking, I first aligned the reads
using STAR, and looked at the STAR QC metrics. Looking at the histogram of
the percentage of mapped reads, it appears that there may be a possible bimodal
distribution — a tight distribution of “high-quality” samples with percentage >
90%, and a “flatter” distribution of samples with a large range of not-so-great
mapped read percentages. This bimodal distribution is troubling, especially if the
two distributions correlate with disease condition (Figure 6.3).
A strip-plot is a great way to get a quick eye-balling of outliers. In Figure 6.4,
we notice that there are outliers for each disease class.
In order to highlight the importance of not relying on just the RIN, I created a
joint plot of the percentage of mapped reads against the RIN (Figure 6.5). There
does not seem to be a clear relationship between the two variables. Therefore, it is
possible that a sample can have a great RIN, but awful mapped read percentage,
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rendering the sample useless for downstream analysis. Running a similar analysis
comparing RIN to the proportion of reads mapping to chrM (the mitochondrial
genome) shows a strong relationship between the two metrics (Figure 6.6).
The aim of this subsection is to determine a list of samples that have outlier QC
values. To get an idea of what the outliers look like, I created a grid of pairwise
scatterplots of five QC metrics (Figure 6.7):
1. Percentage of reads successfully mapped to hg19
2. Average length of mapped read
3. Read mismatch rate
4. Proportion of reads mapping to multiple loci
5. RIN
6. Proportion of reads mapping to chrM
A 5x5 grid of scatterplots is an overwhelming visualization. In an effort to
make the search for outliers easier, I decided to plot the first two components of
the principle component analysis (PCA) of this data (Figure 6.8). Not only do I
get a cleaner visualization of the QC data, this also helps when I run an algorithm
to identify outliers, since I get to avoid the Curse of Dimensionality.
To algorithmically detect outliers, I use a one-class support vector machine
(SVM), trained on the PCA-transformed QC data. The one-class SVM is an unsu-
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pervised machine learning algorithm that attempts to create a higher-dimensional
representation of the data, using a radial basis function. In other words, the al-
gorithm tries to find the “center” of the datapoints in feature space, then draws
a hypersphere around the datapoints, attempting to create the smallest possible
hypersphere able to enclose as many datapoints as possible. Figure 6.9 shows
the heatmap of the one-class SVM outlier predictions. In this way, we are able to
identify 7 outliers that seem to significantly deviate from the rest of the samples.
Plotting these seven outliers on the pairwise scatterplots confirm that these out-
liers are also outliers when considering each QC metric separately (Figure 6.10).
By running the one-class SVM outlier detection algorithm on the PCA-transformed
QC metrics, we were able to identify a set of strange-behaving samples that we
would not have isolated had we simply used a RIN cutoff, or a mapped read per-
centage cutoff. Of course, we will still use a RIN cutoff for downstream analysis,
and if we’re concerned about gene expression, a chrM proportion cutoff would
also make sense (or at least some way of correcting the large number of chrM
reads).
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6.5 Calling and analyzing rare variants in the
Ribo-depleted RNA-seq data
To reiterate — this chapter chronicles my attempt to analyze rare non-coding
variants in a case/control study of schizophrenia. Now that we examined the QC
results of our data, in this section, I will go over the computational pipeline I used
to generate the list of rare variant candidates to consider.
After BAM files are generated by aligning fastq reads using STAR (on GEN-
CODE V19 hg19), the resulting BAM files are sorted and indexed using SAM-
tools. These BAM files are then fed into the three-pass pipeline as described in
section 2.6. The resulting candidate rare variants are prioritized using FATHMM-
MKL [70]. Unlike most variant interpreters, FATHMM-MKL is capable of predict-
ing the functional impact of noncoding variants. This functionality is achieved by
using a training set of noncoding variants, and including features that are avail-
able in noncoding regions, such as the 46-way vertebrate multiple sequence align-
ment, GC content, and features in ENCODE, such as histone modification sites,
open chromatin regions, and transcription factor (TF) binding sites.
Once the rare variants predicted by FATHMM-MKL to be functional are se-
lected, I run a gene-burden test on each gene to determine whether the tested
gene is enriched in rare variants. The resulting set of p-values are then corrected
for multiple tests.
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The subsequent subsections will go into more detail on the rare variant analy-
sis pipeline.
6.5.1 Allele frequency cutoff
Although the three-pass pipeline uses ANNOVAR’s “popfreq max” table to
determine common variants to filter-out, there may be some yet-to-be annotated
common variants, or other common variants that have not been properly an-
notated by ANNOVAR. Also, systematic false positives called by the three-pass
pipeline might also show up as a common variant. Figure 6.11 is an allele fre-
quency histogram of the putative rare variants. Here, the number of putative rare
variants are plotted as a function of the number of samples containing the variant.
For example, there are approximately 10 putative rare variants that are detected
in 300 samples. If ANNOVAR truly removed all known common variants, these
10 putative rare variants must be false positives, and should be removed from
further analysis. To minimize the risk of introducing false positives (or possible
common variants), I removed all variants that have a sample-wide minor allele
frequency greater than 1%.
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Table 6.2: Biotype distribution of putative RiboZero RNA-seq rare variants.
















6.5.2 Biotype distribution of putative rare variants
After removing commonly-occurring variants from the list of putative rare
variants, I used ANNOVAR to annotate the biotype of each variant. Table 6.2
lists the number of variants that fall into each biotype category. As expected, the
number of intronic rare variants dominate all other categories. This may be an
issue when it comes to interpreting the rare variants, as we can expect that most
of these intronic rare variants may be neutral.
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Table 6.3: Number of different types of rare variants detected in the RiboZero
RNA-seq data.




6.5.3 Prioritization of putative rare variants
Since most detected variants are intronic, and there is no expectation for most
of these variants to be functional, it is essential to try and prioritize these vari-
ants. Otherwise, downstream statistical analyses will be polluted with meaning-
less variants, destroying statistical power.
I used FATHMM-MKL to prioritize my variants. FATHMM-MKL uses a sup-
port vector machine (SVM) with features transformed using multiple kernel learn-
ing (MKL). A support vector machine is a supervised machine learning algo-
rithm that attempts to find a hyperplane that best separates the two classes in
feature space. Classically, this classifier is linear (linear-SVM), but by transform-
ing the feature space (the “kernel trick”), SVM is capable of non-linear classifi-
cation [143]. Instead of manually choosing a kernel, FATHMM-MKL uses mul-
tiple kernel learning, which uses a combination of differently-weighted kernels
to transform the data [144]. MKL takes the guesswork out of manually choosing
a static kernel function, and can be advantageous when incorporating heteroge-
neous features, since the optimal kernel can be chosen for each feature type.
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FATHMM-MKL can only handle single nucleotide variants, so I removed 167,265
insertions and deletions from the list of candidate rare variants, and allowed
FATHMM-MKL to prioritize 1,475,530 SNVs. FATHMM-MKL classifies about
56% of exonic rare variants and 5.4% of intronic variants to be deleterious (Figures
6.12 and 6.13).
6.6 Case/control analysis of rare variants in
schizophrenia
Single variant tests are feasible with common variants, but for rare variants, it
is extremely difficult, if not impossible, to see if a singular rare variant is enriched
between two populations, since rare variants are not encountered frequently (by
definition) across individuals.
For rare variant analyses, it is common to consider the entire gene as a singular
unit, and consider all (or any) rare variants in a given gene as affecting gene
function. These statistical tests are called “gene burden” tests.
Gene burden tests can be roughly placed into three categories. Collapsing tests
collect all of the observed rare variants in a single gene in a given sample, and
generates a binary outcome for the gene. The most popular collapsing test is the
CMC test — the CMC scores genes as affected (1) if there is one or more rare vari-
ants observed in a sample, and zero otherwise (no rare variants observed) [145].
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Aggregating tests treat each variant individually, often assigning weights to
the predicted strength of each variant. These variants are then summed to-
gether to determine the aggregate “burden” for a given gene in each sample.
The weighted sum statistic (WSS) was the first weighted aggregating test, where
rarer variants were given a heavier weight [146].
Currently, the most popular test is the sequence kernel association test (SKAT) [147].
SKAT fits a logisitic regression model on the data, incorporating study-specific co-
variates, and the weighted covariance between all observed genotypes.
Since the majority of the rare variants in this study are singular variants, com-
puting the genotype covariance matrix might be of only limited value. Instead,
I decided to use the simplest method, the CMC test, and consider a gene to be
affected if there are one or more rare variants observed in a sample. Since this
is a binary outcome, I created a contingency table of affected/unaffected con-
trols/schizophrenics, and used Fisher’s exact test to test the probability that gene
affectivity is independent from disease status. I also calculated the proportional
difference between cases and controls. This value is positive if more schizophren-
ics are affected than controls, and negative if vice versa. I also ignored genes
that had less than 5% gene affectivity in both groups, since this suggests a lack
of data for that particular gene. Unfortunately, after multiple testing correction
(by using both Bonferroni and Benjamini-Hochberg), no gene remains statistically
significant [106].
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Table 6.4: Genes with greatest proportional difference between schizophrenics &
controls.
HUGO CTRL proportion SCZ proportion Uncorrected p-value Prop. diff.
SYNE1 0.171 0.297 0.0029 0.125
PTPRK 0.143 0.267 0.0024 0.125
PPFIA2 0.057 0.145 0.0033 0.088
LRRC4C 0.139 0.227 0.0257 0.088
DOCK3 0.163 0.250 0.0341 0.086
Figure 6.14 shows a histogram of the proportional differences of gene affec-
tivity between the schizophrenic group and the control group. For example, a
value of 0.0 means that the proportion of samples containing at least one or more
deleterious rare variants in that gene is the same in the schizophrenic and control
groups.
If we create a quantile-quantile plot (QQ-plot) of the proportional differences
against a normal distribution, we notice that the data reflect a gaussian relatively
well, with some possible outliers near the extreme positive end (Figure 6.15).
Table 6.4 lists the top five genes with the greatest proportional difference be-
tween schizophrenics and controls. Of particular note are genes SYNE1 and PT-
PRK, which appear to be outliers when looking at the QQ-plot, with a propor-
tional difference of 0.125.
SYNE1, also known as enaptin, or synaptic nuclear envelope protein 1, is a
nuclear envelope protein, and has been shown to interact with DISC1, a gene
known to be implicated in schizophrenia [148, 149]. SNPs in SYNE1 have been
previously associated with schizophrenia, bipolar disorder, and recurrent major
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depression [150, 151].
99
CHAPTER 6. ANALYSIS OF RARE VARIANTS IN SCHIZOPHRENIA
Figure 6.1: Scatterplots of RiboZero Gold RNA-seq QC metrics. Metrics plot-
ted: Percent mapped reads, proportion of reads mapping to chrM, proportion of
ribosomal RNA, RNA integrity number.
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Figure 6.2: Histogram of the number of variants detected per sample.
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Figure 6.3: Histogram of the percentage of reads successfully mapped in the Poly-
A RNA-seq data.
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Figure 6.4: Strip-plot of mapped read percentage of Phase1 Poly-A RNA-seq data.
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Figure 6.5: Joint density/scatter-plot of the proportion of mapped reads against
the RIN.
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Figure 6.6: Joint density/scatter-plot of the proportion of reads mapping to chrM
against the RIN.
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Figure 6.7: Pairwise scatterplots of five different QC metrics for Phase1 PolyA
RNA-seq data.
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Figure 6.8: PCA of the first two components of five different QC metrics for
Phase1 PolyA RNA-seq data.
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Figure 6.9: One-class SVM heatmap of the first two PCA components of the
Phase1 PolyA RNA-seq QC metrics.
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Figure 6.10: Pairwise correlation plots of 5 QC metrics of the Phase 1 PolyA
RNA-seq QC metrics, colored by outlier membership.
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Figure 6.11: Allele frequency histogram of RiboZero RNA-seq putative rare vari-
ants. A histogram of the number of putative rare variants as a function of the
number of samples containing that variant. For example, there are approximately
10 putative rare variants that are detected in 300 samples.
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Figure 6.12: Histogram of FATHMM-MKL scores for rare exonic SNVs.
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Figure 6.13: Histogram of FATHMM-MKL scores for rare intronic SNVs.
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Figure 6.14: Histogram of gene affectivity differences between cases & controls.
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Analysis of short tandem repeats in
schizophrenia
Variable number tandem repeats (VNTRs) are sometimes overlooked when
studying the etiology of human disease. Of the different types of VNTRs, perhaps
the most commonly studied type are the trinucleotide repeats in coding regions of
the genome, the most well-known instance being the CAG repeat expansion in the
huntingtin (HTT) gene leading to Huntington’s disease [152]. A variety of trinu-
cleotide repeats have been implicated in neurodegenerative disorders, including
spinocerebellar ataxia, fragile X syndrome, and myotonic dystrophy.
Recent improvements in next-gen sequencing (NGS) technologies have made
it possible for short tandem repeats to be interrogated in a genome-wide fash-
ion [15]. With longer read lengths and highly accurate deep sequencing, STRs of
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total length fewer than 85bp are eligible for detection.
Although long VNTRs (including most protein-coding trinucleotide repeat ex-
pansions) are out-of-reach using current NGS methods, STRs remain as an inter-
esting, and possibly promising, field of study. Of particular personal interest are
intronic STRs. Intronic STRs have been previously shown to alter gene function,
and have been implicated in human disease. The following lists a few examples
of functional intronic STRs:
• Intronic CA STRs near the 5’ splice-site have been shown to modulate splic-
ing [153].
• An intronic CA repeat in EGFR ranging between 14 to 21 dinucleotide pairs
has been shown to influence transcription termination closely downstream
of the STR site [154].
• Perturbations of the normal length of a poly-T STR in the polypyrimidine
tract near the 3’ end of intron 4 of MRE11 are associated with significant
impairment of MRE11 expression, suggesting a link to MMR deficient tu-
morigenesis [155].
In this chapter, I will go over a computational pipeline for detecting STRs in
NGS data (and RNA-seq data in particular), and go over some of my work trying
to look for STRs significantly altered between cases & controls.
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7.1 Calling STRs in NGS data
Short tandem repeats were traditionally examined by either individually screen-
ing them through Sanger sequencing, or by polling the global STR content through
the use of microarrays [156]. With new NGS technologies and software pipelines,
it is now possible to interrogate almost all short tandem repeats in the genome
with relatively high confidence, outstripping Sanger sequencing in terms of through-
put and cost, and with significant advantages over the use of microarrays, since
with NGS, we are able to directly infer the genotype of each allele, instead of
merely having a global picture of the abundance of each STR motif.
There are currently two bioinformatics tools for calling STRs in NGS data. Re-
peatSeq uses a Bayesian error model on already-aligned reads containing STRs to
determine the accuracy of a particular STR candidate [157]. LobSTR works with
the fastq file directly, aligning reads containing repetitive regions to the refer-
ence genome by using the sequences flanking the STR. Once the reads have been
aligned to candidate STR regions, the alleles are estimated using a model of the
stutter noise generated through multiple PCR runs [158].
Although these tools have been evaluated on whole genome sequencing data
and whole exome sequencing data, to my knowledge, they have not been applied
to RNA-seq data. In spite of this, I do not expect any serious complications, since
the main difference in RNA-seq data is the inclusion of reads spanning a splice
junction. In the case for lobSTR, these reads would simply appear to have a giant
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deletion (of the intron), and would most likely be treated as being unalignable.
There is a small risk that these reads might be misaligned, which could raise a
false-positive. Again, I am not too concerned about this issue, because STRs are
strongly depleted in coding regions (there are only a few thousand STRs in the
coding regions of the human genome, compared to over 400,000 STRs genome-
wide), so the likelihood that a junction-spanning read just happens to become
misaligned, and also just happens to contain a STR is vanishingly small.
Figure 7.1: Histogram of repeatmasker STRs of different motif sizes as a function
of length. STR motifs range from 1 base to 6 bases in length.
Figures 7.1 and 7.2 highlight my previous point about STR depletion in coding
regions. Genome-wide, dinucleotide repeats are significantly more prevalent than
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Figure 7.2: Histogram of repeatmasker STRs in coding regions of different motif
sizes as a function of STR length. STR motifs range from 1 base to 6 bases in
length.
other types of STRs, but in coding regions, there are practically no STRs that
are not trinucleotide or hexanucleotide repeats. This is because expansions and
contractions of tri- and hexa-nucleotide repeats preserve the reading frame of the
transcript, but most expansions/contractions of the other STR types will result in
a frameshift, most likely destroying the function of the gene. Also note that the
total number of STRs in the coding region is several orders of magnitude lower
than the number of STRs in noncoding regions of the genome.
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For the purposes of this study, I decided to use lobSTR instead of Repeat-
Seq, due to the fact that lobSTR is significantly faster than RepeatSeq, and also
provides tools for modeling the allelotype distribution of each STR variant.
In order to test the feasibility of calling STRs in RNA-seq data, I ran the lobSTR
pipeline on a subset of the PolyA RNA-seq data. Figures 7.3 and 7.4 show the
histograms of all STRs in hg19 and all detected STRs in the PolyA RNA-seq data.
Figure 7.4 also shows a gradual cutoff in the number of STRs detected with total
length greater than 100bp. This is due to a technical limitation of NGS: with
100bp reads, it is almost impossible to fully characterize a STR longer than 100bp,
and slightly shorter STRs (between 80-95bp in length) will not have enough bases
from the flanking regions for any aligner to uniquely map the read to the reference
genome.
The previously provided reasons do not explain why we are able to pick up
any STRs longer than 100bp. We are able to pick up a small proportion of > 100bp
STRs because we are using paired-end 2x100bp reads. If we know the insert size
of the read, and the paired-end reads just happen to span the entire length of the
STR (STR start at one paired-end read, STR end at the other paired-end read), then
it is possible to infer the actual length of the STR, provided that the alignment is
done successfully.
In order to poll STRs between schizophrenics and matched controls, I ran
lobSTR with default settings on fastq files of both PolyA RNA-seq data and of
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RiboZero RNA-seq data. The fastq files were stored and analyzed on a Dell Pow-
eredge R910, configured with 1TB of DDR3 RAM, containing four ten-core Intel
Xeon processors, and capable of processing 80 threads in parallel. I ran lobSTR
jobs in parallel using GNU parallel [159]. I was particularly interested in the Ri-
boZero RNA-seq data, because of RiboZero’s ability to detect intronic regions
with greater overall coverage. In the PolyA RNA-seq data, I was able to create
genotype predictions of 73,025,743 STRs in 822 samples, producing an average
of 88,839 STRs per sample. In the RiboZero RNA-seq data, lobSTR was able to
detect 145,254,858 STRs in 500 samples, producing an average of 290,510 STRs per
sample.
Although RiboZero is capable of picking up reads from intronic regions, due
to the immense length of most introns, the overall coverage of most intronic STRs
is a bit spotty. Figure 7.5 highlights this issue. Although there are STRs that can
be detected in all 500 RiboZero RNA-seq samples, there are also a lot of STRs that
can only be detected in a handful of samples. These STRs need to be removed
from downstream statistical analysis.
7.2 Storage of STRs in SQL database
With such a large number of variants detected in the data (over 145 million
STRs genotyped), it is essential to store the data in a structured, index-able way.
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To this end, I created a python script capable of parsing and uploading VCF files
into a MySQL database. In order to parse the VCF file, I used PyVCF, which
parses each VCF line into a Record object, which allows for easy downstream
parsing [160]. I also used the SQLalchemy module for Python, which provides
an extremely flexible wrapper around many different flavors of SQL, allowing
for easy transition between database systems such as SQLite, MySQL, and Post-
gres [161].
7.3 Annotation and statistical analysis of STRs
Once the STRs are stored in the database, I also annotated each detected STR
using ANNOVAR to determine its biotype. Figure 7.6 shows boxplots of the
number of samples that can detect a given STR, separated by biotype. In this
figure, we can see that the intergenic STRs are hard to detect, highlighted by the
low number of samples. Due to RNA-seq’s design, we also see that, as expected,
we can call STRs in exonic, UTR3, and UTR5 areas with high sensitivity. Due to
the fact that most ncRNAs are lowly expressed, we also observed a relatively low
sensitivity when detecting STRs in ncRNAs. It also appears that intronic STRs
also fall into this “difficult to detect” category, with a median intronic STR being
detectable by about 140/500 samples.
In order to try and detect possibly significant STRs between cases and controls,
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for each STR, I ran a Wilcoxon rank sum test. The Wilcoxon rank sum test, also
known as the Mann-Whitney U test, is a nonparametric test that calculates the
likelihood that the two samples of data originate from the same population distri-
bution [162]. Since the ranksum test is a nonparametric test, very few assumptions
need to be made on the data. For each STR, we cannot make the assumption that
the distribution of alleles follow a normal distribution, or that both distributions
have the same variance — therefore, we cannot, in good faith, run a t-test on the
data. The ranksum test asks for these assumptions on the data:
• All data points are independent and identically distributed (iid)
• Data fall on an ordinal scale (we can say data point x is greater, or smaller
than, y)
• The null hypothesis states that the distributions of both populations are
identical
STR allele data can satisfy these conditions, and so I conducted 329,352 ranksum
tests on the data, removing 35,097 intergenic STRs. Due to the limitations of the
ranksum test, and to try and mitigate the low sensitivity of intronic STR detec-
tion, I only chose to run statistical testing on STRs that were observed in at least
40 schizophrenics and 40 controls. I chose a subset of the RNA-seq data, of cau-
casian individuals with age greater than 16. Individuals with age less than 16
would be ambiguous in terms of diagnosis, since the onset of schizophrenia usu-
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Table 7.1: Most significant STRs in RiboZero RNA-seq case/control study.
chrom pos biotype hugo motif ref qval
chr16 75673678 intronic KARS A 19 0.0025
chr15 59643060 ncRNA intronic MYO1E lncRNA AAC 5.667 0.0055
chr3 172020666 intronic FNDC3B AC 21.5 0.0067
chr4 56309643 intronic CLOCK, TMEM165 A 24 0.0260
chr17 26657086 intronic IFT20 A 17 0.0530
chr1 47125640 intronic ATPAF1, EFCAB14 AAAG 3.75 0.0697
chr8 30554930 intronic GSR AAAC 11.25 0.0944
chr8 26698107 intronic ADRA1A A 13 0.1027
chr7 123907559 ncRNA intronic RP5-921G16.1 A 14 0.1041
chr3 17549509 intronic TBC1D5 A 11 0.1050
chrX 21978155 intronic SMS AC 7 0.1372
chr19 9755727 intronic C19orf82 A 16 0.1601
chr3 62251572 ncRNA intronic PTPRG-AS1 AC 15 0.1758
chr3 113052803 intronic WDR52 A 16 0.2216
chr19 19780721 intronic ZNF101 A 12 0.2276
ally happens after the age of 16. The youngest individual in our dataset diagnosed
with schizophrenia is 16 years of age, which is the main motivator for my choos-
ing of this hard boundary. Caucasians were also chosen for the initial round of
STR testing, as I was concerned that analyzing the samples as a whole would be
confounded by racial differences that are reflected in the STR landscape.
Figure 7.7 shows that there is a significant enrichment for low p-values than
one would expect by chance — for a truly null distribution, one would expect a
uniform distribution of p-values. After Bonferroni correction, four STRs remain
statistically significant. Bonferroni is an overtly conservative correction technique,
and it is likely that there are more STRs that should be labeled as statistically
significant. The most statistically significant STRs are shown in Table 7.1.
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7.4 Analysis of significant genes
The most significant STR is an intronic poly-A stretch (with a cytosine an-
chor) inside KARS. This STR also happens to occur at the very 3’ end of a re-
cently discovered retained intron transcript, ENST00000565738 (Figure 7.8 shows
a snapshot of the region in the UCSC genome browser). KARS, also known as
lysyl-tRNA synthetase, primarily acts to ligate lysine to its corresponding tRNA,
but has also been shown to act as a signaling molecule, inducing the primary
immune response by activating monocytes [163,164]. Mutations in the aminoacyl
tRNA synthetase family have been linked to neuronal pathologies, autoimmune
disorders, and cancer [165]. Interestingly, KARS has been shown to be necessary
for HIV viral assembly, interacting with Gag [166]. Figure 7.9 shows the distribu-
tion of alleles of the KARS STR in our study.
The second most significant STR is an AAC repeat residing in an intron of an
intronic ncRNA (RP11-356M20.3), which is itself inside the first intron of MYO1E
(UCSC snapshot in Figure 7.10. MYO1E has been shown to regulate the TLR4-
triggered macrophage response [167]. Mutations in MYO1E have also been asso-
ciated to glomerulosclerosis [168]. This is a bit of a long shot, but in a Taiwanese
matched cohort study of schizophrenics and controls, after controlling for covari-
ates, the schizophrenic hazard ratio for the development of chronic kidney disease
(CKD) was 1.25 (p < 0.05) [169].
Some of the other genes in the top most significant list are also interest-
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ing. The CLOCK gene regulates circadian rhythm, and has previously been im-
plicated in bipolar disorder and major depressive disorder. Schizophrenia has
been previously shown to be co-morbid with sleep and circadian rhythm disrup-
tion [170–172]. IFT20 codes for a intraflagellar transport protein, and evidence
suggests IFT20 to regulate the immune synapse assembly in T cells. IFT20 has
also been shown to interact with DISC1, a known schizophrenia gene [149].
Perusal of the top most significant genes in this analysis all have some link to
the immune response, which I find interesting, as there is a previously established
link between schizophrenia and the immune response. Müller et al. revealed that
schizophrenics suffer from impaired monocyte activation, with an abnormally
high level of TLR3 and TLR4 receptors [173]. Several other studies also suggest
impaired monocyte function in schizophrenics [174–176]. Macrophages have also
been shown to follow a circadian cycle [177].
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Figure 7.3: Histogram of all repeatmasker STRs in hg19 as a function of STR
length.
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Figure 7.4: Histogram of all detected STRs in a subset of PolyA RNA-seq data as
a function of STR length.
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Figure 7.5: Histogram of the number of RiboZero RNA-seq samples detecting a
given STR.
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Figure 7.6: Boxplots of the number of samples that detect a given STR, separated
by biotype.
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Figure 7.7: Distribution of uncorrected p-values comparing STRs of cases vs. con-
trols.
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Figure 7.8: UCSC genome browser snapshot of KARS. Statistically significant STR
is highlighted in blue.
132
CHAPTER 7. ANALYSIS OF SHORT TANDEM REPEATS IN
SCHIZOPHRENIA
Figure 7.9: Distribution of alleles in significant KARS STR. The x axis measures
the base length difference from hg19 reference.
Figure 7.10: UCSC genome browser snapshot of MYO1E. Statistically significant




8.1 Refinement of rare variant calling pipeline
The three-pass rare variant calling pipeline is in a very early prototypical stage,
and I have in mind various improvements and simulations that can be done that
may improve the pipeline significantly.
8.1.1 Choice of aligner
For the three-pass pipeline I chose STAR as the initial aligner, GSNAP as my
secondary aligner, and BLAT as my final aligner. It may be worthwhile to run a
permutation study, using the many different RNA-seq aligners available today. I
chose these aligners for my initial build of the pipeline for the following reasons:
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• STAR is two orders of magnitude faster than any other split-read aligner. I
lacked the time and computational resources to use a different aligner for
the first pass of calling rare variants. Fortunately, STAR turns out to perform
quite well, with sensitivity and specificity similar to that of TopHat.
• GSNAP has the best alignment specificity. Although slower than most RNA-
seq aligners, GSNAP does a good job reducing the number of false positives.
• BLAT has great sensitivity. Since I wanted to make sure candidate variant
regions are uniquely mappable, I used BLAT to discover as many alignment
alternatives as possible.
8.1.2 Choice of variant caller
I chose Platypus as my variant caller, since it was up to 10 times faster than the
next fastest candidate, freebayes. Ideally, one would most likely want to choose a
high-sensitivity variant caller for the “first pass,” then go for a variant caller with
great specificity (and sensitivity, if possible) on subsequent passes. Platypus had
great specificity, but the hit to sensitivity was quite extreme, at around 50%. In
future runs, I would most likely test freebayes first, since it looks like freebayes
has good sensitivity, and then perhaps run the second pass using GATK’s Haplo-
typeCaller. HaplotypeCaller has a reputation for having both good sensitivity and
specificity, but due to speed requirements, I decided to go for Platypus instead.
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8.1.3 Incorporation of variant calling into the align-
ment process
I think it is a mistake for variant callers to conflate rare variants with common
variants. I imagine that the primary aim for most users of NGS variant-calling
tools are using them to exclusively find rare variants, not common variants. If
somebody is only interested in common variants, then they would save a lot of
money using a SNP chip, instead of NGS.
While I was writing this dissertation, attempting to figure out summary statis-
tics for common and rare variants, I thought of an idea that may streamline the
variant-calling process. Earlier in this thesis, I wrote that the average individual
has about 3.4 million SNPs, and about 300,000 rare variants. That means that
the typical variant-calling pipeline spends more than 90% of its time trying to
characterize common variants, even though over 90% of the users are probably
only interested in the rare variants. Since, by definition, these common variants
are encountered frequently in sequencing studies, perhaps we can “anticipate”
the arrival of these common variants and include them as part of the reference
genome, when building indexes for alignment software. In other words, in addi-
tion to the typical chromosomal fasta entries in the reference, we could add in 4.3
million “pseudochromosomes” of SNPs (and their flanking regions) into the hu-
man reference, and then align reads to this combined reference. By doing this, we
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can achieve two things. We quickly dispatch the discovery of common variants,
hopefully reducing the workload of the downstream variant caller by an order of
magnitude. We also can improve the specificity of calling these common variants,
since misalignments will be addressed as part of the index-building process.
Another advantage of this step is that it is variant-caller agnostic; this can
be a stand-alone tool that will dispatch the known common variants in a given
fastq file, and then the user can choose a favorite variant caller tool to process
the subsequent BAM file for rare variants, with the satisfaction that the variant-
calling tool might perform up to 10x faster. Of course, the alignment step will
be significantly slower, but since the alignment step is already extremely fast
(especially when using STAR), I think the loss in alignment speed will be more
than made up by the gains in variant calling speed.
8.2 Analysis of rare variants in schizophre-
nia
I called the rare variants in the case/control schizophrenia RNA-seq dataset
using my prototype three-pass pipeline. In the previous section, I have listed sev-
eral improvements for the pipeline, and I believe improvements to that pipeline
may make significant improvements to this analysis as well. Since I took a 50%
hit to sensitivity by using Platypus, changing the variant caller to freebayes or Hap-
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lotypeCaller may significantly improve statistical power.
8.2.1 Use of other variant annotation/interpretation tools
For my initial analysis, I used FATHMM-MKL to select for putative functional
variants. One possible weakness of using FATHMM-MKL is that it is trained on
mainly features originating from ENCODE. It might be worthwhile to incorporate
other variant annotation tools. One tool that comes to mind would be a recent
tool that uses a deep neural network to discover many intronic variants that affect
splicing [141]. It might also be worthwhile to incorporate other features, such as
those regions found to interact with MECP2 or TDP-43.
8.2.2 Using a more sophisticated gene model
Instead of using CMC, which is the simplest gene burden method, it might be
worthwhile to use an additive method that perhaps incorporates the variant scores
from various annotation tools. It might also make sense to try and incorporate
positional clustering as a possible feature, in the sense that functional rare variants
may tend to cluster around functional regions of a gene.
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8.2.3 Incorporation of gene fusions and expression data
RNA-seq is also capable of detecting gene fusions, which tend to significantly
alter the genes. Since CNVs have been implicated in schizophrenia in the past, it
might be worthwhile to also determine the impact of gene fusions in schizophre-
nia.
Using the RNA-seq expression data would also add another dimension to
the analysis. If the existence of a rare variant also corresponds to a significant
alteration of alternative splicing, this might be evidence to suggest that the rare
variant in question might be functional. Care must be taken when doing this
analysis, though. Using the same reads to quantify alternative splicing as well
as doing rare variant calling might introduce hidden confounders that affect both
variables. One way to mitigate this would be to use the set of brain samples
that have had both Poly-A RNA-seq and RiboZero RNA-seq. The RiboZero data
would be used to call the variants, and the Poly-A data could be used to quantify
alternative splicing.
8.3 Determining viral load using RNA-seq
This is probably a long-shot, but in light of some “out-there” hypotheses posit-
ing a link between early viral exposure to schizophrenia, I thought it might be
worthwhile to quickly take a peek at the RNA-seq data that we have, to get an
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idea if there’s any sort of viral signature in the dataset. Executing this would be
a pretty simple matter. All of the data has already been aligned to the human
reference using TopHat. TopHat, by default, outputs a file of unmapped reads —
reads that failed to map to the human genome. It would be a relatively simple
matter to download all known viral genomes, index the file, and align the remain-
ing unmapped reads to this reference. Some tweaks would be necessary, such as
allowing the aligner to map to multiple viral genomes, since we don’t want to
throw away any reads that happen to map to multiple areas.
Once the alignment is complete, we can collect the data, calculate expression
values (perhaps a metric such as TPM would be more informative), and look to
see if there is any viral reads, and if so, whether any particular virus is enriched
between cases and controls.
8.4 Analysis of short tandem repeats in schizophre-
nia
The short tandem repeat analysis has one major weakness, which is the low
sensitivity for calling most intronic variants in the RiboZero data. Unfortunately,
this is a weakness of the sequencing technology, and short of increasing the numer
of mapped reads (which is already a pretty deep 80-100 million reads per sample),
there is not much we can do about this, unless we transition to whole genome
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sequencing.
The short tandem repeat analysis, as well as the rare variant analysis, suf-
fer from a major confounder, which is expression: If the gene is not transcribed,
there is no way RNA-seq can call variants in the gene. If the gene is differen-
tially expressed between cases and controls, then this may also bias rare variant
detection. One way to mitigate this would be to only select for genes/regions that
have relatively medium-to-high expression, so that the detection rate minimally
suffers from confounding. I tried to account for this in the data by enforcing a
high coverage cutoff, but this only mitigates the danger.
8.4.1 Development of a more sophisticated STR al-
lelotype model
For my initial STR analysis, I made practically no assumptions about the dis-
tribution of alleles of a given STR, and used the Mann-Whitney U test. Instead, I
think it is worthwhile to use the thousand genomes data to get a prior distribu-
tion of alleles for a given STR. The control samples could then be used to verify
the “null” distribution, and we can then get a more meaningful measure of STR
variability.
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8.4.2 Validation of called STRs
Since RiboZero RNA-seq only provides modest intronic coverage, for a given
STR, there will most likely be a bunch of samples where there was insufficient
coverage to determine the STR of interest. It might be worthwhile to validate
these regions using vanilla sanger sequencing. Perhaps there might be a way to
create a “STR-capture” technique similar to exome capture techniques.
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